var title_f12_55_13168="Child upper GI anatomy PI";
var content_f12_55_13168=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F52952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F52952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Upper digestive system in a child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 486px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing shows where the esophagus, stomach, and small intestine are located in a child.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_55_13168=[""].join("\n");
var outline_f12_55_13168=null;
var title_f12_55_13169="CT scan showing pancreatic necrosis";
var content_f12_55_13169=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F62632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F62632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT scan showing pancreatic necrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Contrast-enhanced computed tomography (CECT) scan showing perfused pancreatic tissue (arrow) and nonperfused pancreatic necrosis (star) with associated peripancreatic necrosis (triangle) in the transverse mesocolon of a patient with severe acute pancreatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_55_13169=[""].join("\n");
var outline_f12_55_13169=null;
var title_f12_55_13170="Bentoquatam: Drug information";
var content_f12_55_13170=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bentoquatam: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/8/25731?source=see_link\">",
"    see \"Bentoquatam: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F139756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ivy Block&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F139765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F139757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of contact dermatitis: Topical: Apply to skin 15 minutes prior to potential exposure to poison ivy, poison oak, or poison sumac, and reapply every 4 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F139762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &gt;6 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F139758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F139749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ivy Block&reg;: 5% (120 mL) [contains benzyl alcohol, ethanol 25%]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F139738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F139750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Skin protectant for the prevention of allergic contact dermatitis to poison oak, ivy, and sumac",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F139764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     &lt;1% (Limited to important or life-threatening): Erythema",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F139753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bentoquatam or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F139742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergic-type responses: Use with caution in patients with history of allergic-type responses to medications (especially topical formulations).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cutaneous conditions: Use with caution in patients with open wounds, psoriatic lesions, or other cutaneous conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Poison oak/ivy/sumac: Use with caution in patients who are postexposure to poison oak, ivy, or sumac (lack of efficacy).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Ivy Block External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (120 mL): $7.17",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F139747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of exposure to poison oak, ivy, or sumac (rash, swelling, blisters)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F139741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An organoclay substance which is capable of absorbing or binding to urushiol, the active principle in poison oak, ivy, and sumac. Bentoquatam serves as a barrier, blocking urushiol skin contact/absorption.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F139752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Has not been studied",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8597 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-27EA24A548-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_55_13170=[""].join("\n");
var outline_f12_55_13170=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139756\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139765\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139757\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139762\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139758\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139749\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139738\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139750\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139764\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139753\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139742\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298829\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218286\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323011\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139747\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139741\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139752\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8597\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8597|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/8/25731?source=related_link\">",
"      Bentoquatam: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_55_13171="Penicillins and cephalosporins - common side chains";
var content_f12_55_13171=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F65497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F65497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 634px\">",
"   <div class=\"ttl\">",
"    Side chains shared by penicillins and cephalosporins",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 614px; height: 792px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Some penicillins and cephalosporins share identical or similar side chain groups, leading to possible clinical cross-reactivity. Ampicillin has the same side chain in the R1 position as cephalexin and cefaclor, as well as (not shown) cephradine, cephaloglycin, and loracarbef. Amoxicillin has the same side chain as cefadroxil, cefatrizine, and (not shown) cefprozil.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Antonino Romano, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_55_13171=[""].join("\n");
var outline_f12_55_13171=null;
var title_f12_55_13172="Methyl salicylate and menthol: Patient drug information";
var content_f12_55_13172=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Methyl salicylate and menthol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/26/21923?source=see_link\">",
"     see \"Methyl salicylate and menthol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8116108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      BenGay&reg; [OTC];",
"     </li>",
"     <li>",
"      Icy Hot&reg; [OTC];",
"     </li>",
"     <li>",
"      Precise&reg; [OTC];",
"     </li>",
"     <li>",
"      Salonpas&reg; Arthritis Pain&reg; [OTC];",
"     </li>",
"     <li>",
"      Salonpas&reg; Jet Spray [OTC];",
"     </li>",
"     <li>",
"      Salonpas&reg; Massage Foam [OTC];",
"     </li>",
"     <li>",
"      Salonpas&reg; Pain Relief Patch&reg; [OTC];",
"     </li>",
"     <li>",
"      Thera-Gesic&reg; Plus [OTC];",
"     </li>",
"     <li>",
"      Thera-Gesic&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691600",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain and swelling.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to methyl salicylate, menthol, NSAIDS, salicylate, aspirin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 24 weeks pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696732",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on irritated skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin patch:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The patch may have metal. Take off the patch before an MRI.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin patch:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694513",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on clean, dry, healthy skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin patch:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part of opened pouch that is not used after 2 weeks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12249 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-F0C764AA00-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_55_13172=[""].join("\n");
var outline_f12_55_13172=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116108\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022443\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022442\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022447\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022448\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022450\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022445\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022446\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022451\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022452\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/26/21923?source=related_link\">",
"      Methyl salicylate and menthol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_55_13173="CT scan acute calculous cholecystitis";
var content_f12_55_13173=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F77336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F77336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    Computed tomographic (CT) scan from a patient with acute cholecystitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The CT scan shows a distended gallbladder with an edematous and hyperemic wall (thick yellow arrow) and inflammatory induration in the fat surrounding the gallbladder (yellow arrowheads). A calcified stone is visible lying dependently at the base of the gallbladder (thin yellow arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_55_13173=[""].join("\n");
var outline_f12_55_13173=null;
var title_f12_55_13174="Acanthamoeba life cycle";
var content_f12_55_13174=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70542&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70542&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 600px\">",
"   <div class=\"ttl\">",
"    Acanthamoeba life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 580px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <em>",
"     Acanthamoeba",
"    </em>",
"    spp have been found in soil; fresh, brackish, and sea water; sewage; swimming pools; contact lens equipment; medicinal pools; dental treatment units; dialysis machines; heating, ventilating, and air conditioning systems; mammalian cell cultures; vegetables; human nostrils and throats; and human and animal brain, skin, and lung tissues. Unlike",
"    <em>",
"     N. fowleri",
"    </em>",
"    ,",
"    <em>",
"     Acanthamoeba",
"    </em>",
"    has only two stages, cysts",
"    <strong>",
"     (1)",
"    </strong>",
"    and trophozoites",
"    <strong>",
"     (2)",
"    </strong>",
"    , in its life cycle. No flagellated stage exists as part of the life cycle. The trophozoites replicate by mitosis (nuclear membrane does not remain intact)",
"    <strong>",
"     (3)",
"    </strong>",
"    . The trophozoites are the infective forms, although both cysts and trophozoites gain entry into the body",
"    <strong>",
"     (4)",
"    </strong>",
"    through various means. Entry can occur through the eye",
"    <strong>",
"     (5)",
"    </strong>",
"    , the nasal passages to the lower respiratory tract",
"    <strong>",
"     (6)",
"    </strong>",
"    , or ulcerated or broken skin",
"    <strong>",
"     (7)",
"    </strong>",
"    . When",
"    <em>",
"     Acanthamoeba",
"    </em>",
"    spp enters the eye, it can cause severe keratitis in otherwise healthy individuals, particularly contact lens users",
"    <strong>",
"     (8)",
"    </strong>",
"    . When it enters the respiratory system or through the skin, it can invade the central nervous system by hematogenous dissemination, causing granulomatous amebic encephalitis (GAE)",
"    <strong>",
"     (9)",
"    </strong>",
"    or disseminated disease",
"    <strong>",
"     (10)",
"    </strong>",
"    , or skin lesions",
"    <strong>",
"     (11)",
"    </strong>",
"    in individuals with compromised immune systems.",
"    <em>",
"     Acanthamoeba",
"    </em>",
"    spp cysts and trophozoites are found in tissue.",
"    <div class=\"footnotes\">",
"     * Results in severe keratitis of the eye",
"     <strong>",
"      (8)",
"     </strong>",
"     .",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Results in granulomatous amebic encephalitis",
"      <strong>",
"       (9)",
"      </strong>",
"      (GAE) and/or disseminated disease",
"      <strong>",
"       (10)",
"      </strong>",
"      in individuals with compromised immune systems.",
"      <br>",
"       &Delta; Results in granulomatous amebic encephalitis",
"       <strong>",
"        (9)",
"       </strong>",
"       (GAE), disseminated disease",
"       <strong>",
"        (10)",
"       </strong>",
"       , or skin lesions",
"       <strong>",
"        (11)",
"       </strong>",
"       in individuals with compromised immune systems.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites: Acanthamoeba. Available at:",
"     <a href=\"file://www.cdc.gov/parasites/acanthamoeba/biology.html\" target=\"_blank\">",
"      file://www.cdc.gov/parasites/acanthamoeba/biology.html",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_55_13174=[""].join("\n");
var outline_f12_55_13174=null;
var title_f12_55_13175="Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use";
var content_f12_55_13175=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/55/13175/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/55/13175/contributors\">",
"     Guy S Reeder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/55/13175/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/55/13175/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/55/13175/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/55/13175/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/55/13175/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of therapies are beneficial in the management of patients with acute myocardial infarction (MI), including revascularization with either percutaneous coronary intervention or fibrinolysis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , beta blockers, statins, and either angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most randomized trials of ACE inhibitors or ARBs started within 24 hours to 16 days following an acute MI showed an improvement in left ventricular ejection fraction (LVEF) at one month to one year. In addition ACE inhibitors improve survival for at least one year and probably longer. The magnitude of the survival benefit at 12 months is approximately 0.5 percent (12 versus 12.5 percent in the placebo group). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=see_link&amp;anchor=H2#H2\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials\", section on 'ACE inhibitor effects on cardiac function and mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recommendations for the use of ACE inhibitors and ARBs after MI will be reviewed here. The clinical data supporting the efficacy of these agents in this setting and the possible mechanisms by which ACE inhibitors might act are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1799?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors in acute myocardial infarction: Mechanisms of action\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVIDENCE OF BENEFIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence from randomized trials of either ACE inhibitors or ARBs compared to placebo demonstrates an improvement in mortality. In a meta-analysis of nearly 100,000 patients from four randomized trials in which ACE inhibitor was started within 36 hours of myocardial infarction, 30 day mortality significantly lower in treated patients compared to controls (7.1 versus 7.6 percent; RR 0.93, 95% CI0.89-0.98). [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13175/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=see_link&amp;anchor=H2#H2\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials\", section on 'ACE inhibitor effects on cardiac function and mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Randomized trials such as SAVE or AIRE have specifically evaluated patients with either heart failure or reduced left ventricular ejection fraction and found a significant reduction in the risk of death with ACE inhibitor therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=see_link&amp;anchor=H4#H4\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials\", section on 'Low ejection fraction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=see_link&amp;anchor=H5#H5\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials\", section on 'Heart failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When all trials of ACE- inhibitors or ARBs are considered, the benefit of these therapies is greater for patients with a reduced left ventricular ejection fraction (LVEF) or heart failure than for patients with normal or near normal LVEF [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13175/abstract/2\">",
"     2",
"    </a>",
"    ]. The meta-analysis discussed above found that there was no significant difference in the relative risk reduction in the subgroup of patients with heart failure (compared to those without); however, the absolute benefit was greater in this group given the higher baseline risk (14.0 versus 15.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13175/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the pivotal ISIS-4 and GISSI-3 trials, the two largest studies, the great majority of patients had an ST elevation MI (STEMI). Data on the efficacy and safety of these therapies are limited in patients with a non-ST elevation acute coronary syndrome (NSTEMI) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13175/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition most patients were treated with either fibrinolytic therapy or no reperfusion; data in patients who underwent percutaneous coronary intervention (PCI) for MI are limited. We do not believe there is evidence to support separate recommendations for the use of ACE-I or ARBs in patients with NSTEMI.",
"   </p>",
"   <p>",
"    The following approach for the use of ACE-I and ARBs in patients with acute MI is consistent with recommendations made in American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13175/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initiation of ACE inhibitors is recommended in all patients with an acute MI who are not at lower risk; lower risk was defined as a normal left ventricular ejection fraction (LVEF), well-controlled cardiovascular risk factors, and performance of revascularization. For lower risk patients, we suggest ACE inhibitor therapy.",
"     </li>",
"     <li>",
"      Angiotensin II receptor blockers (ARBs) are recommended in patients who are intolerant of angiotensin converting enzyme (ACE) inhibitors and have clinical or radiologic signs of heart failure, an left ventricular ejection fraction &le;40 percent, or hypertension.",
"     </li>",
"     <li>",
"      The combined use of both ACE inhibitors and ARBs in STEMI patients with systolic dysfunction is discussed below. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'ACE-I versus ARB'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications for the administration of an ACE inhibitor include allergy to ACE inhibitors, hypotension (systolic blood pressure less than 90 to 100 mmHg or systolic pressure &ge;30 mmHg below baseline), shock, history of bilateral renal artery stenosis, and prior worsening of renal function with ACE inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13175/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of impaired renal function alone is not a contraindication to the use of ACE inhibitors or ARBs. In a retrospective cohort study of over 20,000 patients &ge;65 years of age with myocardial infarction and impaired left ventricular function, administration of an ACE inhibitor was associated with a survival benefit, even in patients with serum creatinine concentrations above 3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (265",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13175/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TIMING OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy with ACE inhibitor has been shown to be beneficial when administered either early or late. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=see_link&amp;anchor=H9#H9\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials\", section on 'TIming of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The large GISSI-3, and ISIS-4 trials evaluated the administration of ACE inhibitors within 24 hours of presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13175/abstract/3,9,10\">",
"     3,9,10",
"    </a>",
"    ] and found that approximately 30 percent of the total mortality reduction occurred within 24 hours of symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13175/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a meta-analysis of four smaller trials of late administration of ACE inhibitor (more than 48 hours), therapy was associated with a significant reduction in 1-year mortality (14.3 versus 16.5 percent; OR 0.84, 95% CI 0.73 to 0.97) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13175/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on this evidence, we suggest starting therapy within 24 hours in stable patients with MI; this recommendation is consistent with that made in the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guideline on STEMI [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13175/abstract/4,6\">",
"     4,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DOSING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safe use of ACE inhibitors soon after acute MI requires oral administration at low doses with careful monitoring of the blood pressure. Recommended initial regimens include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    (initial dose of 6.25 mg, which is increased at six to eight hour intervals to a maximum of 50 mg three times daily as long as the systolic blood pressure is above 90 to 100 mmHg),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    (initial dose 2.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    increased up to 20 mg twice daily), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    (initial dose 2.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    increased to a maximum of 10",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    In some patients, attainment of these doses requires the weaning of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    (in the absence of ongoing ischemia) and reduction or elimination of diuretics. Neither ISIS-4 nor GISSI-3 demonstrated mortality reduction from the use of nitrates in the absence of ongoing ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13175/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. It may therefore be preferable to decrease the routine utilization of these agents in favor of ACE inhibition when blood pressure considerations are limiting.",
"   </p>",
"   <p>",
"    Although different ACE inhibitors show differences in their affinity for the cardiac renin-angiotensin system [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13175/abstract/13\">",
"     13",
"    </a>",
"    ], the protective effects post-MI appear to be a class effect and all ACE inhibitors are likely to be equally effective.",
"   </p>",
"   <p>",
"    The use of an intravenous ACE inhibitor is",
"    <strong>",
"     not",
"    </strong>",
"    recommended because of the risk of hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13175/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DURATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of treatment in many of the relevant trials of ACE-inhibitors or ARBS after MI was four to six weeks. In one MI trial (VALIANT) approximately 90 percent of patients were taking either study drug or open-label ACE-inhibitor at one year.",
"   </p>",
"   <p>",
"    The benefits of long-term therapy with an ACE inhibitor or ARB have been demonstrated for patients with a specific indication for such therapy, such as heart failure, diabetes, vascular disease, hypertension, or chronic kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2680?source=see_link&amp;anchor=H24#H24\">",
"     \"Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20218?source=see_link&amp;anchor=H16#H16\">",
"     \"Choice of therapy in essential hypertension: Clinical trials\", section on 'ONTARGET trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    and (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=see_link&amp;anchor=H24#H24\">",
"     \"Microalbuminuria in type 2 diabetes mellitus\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    We recommend indefinite therapy with ACE-inhibitor or ARB after MI in most patients. This approach is consistent with that given by in the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13175/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. In those patients at lower risk (a normal left ventricular ejection fraction (LVEF), well-controlled cardiovascular risk factors, and performance of revascularization) the benefits of long-term therapy should be weighed against the potential burdens (side effects, complicated medical regimens, or financial concerns) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13175/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ACE-I VERSUS ARB",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two randomized trials (OPTIMAAL and VALIANT) that compared outcomes after either ACE-I or ARB enrolled only high-risk (heart failure or anterior MI) patients and found no significant difference in mortality between the two therapies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=see_link&amp;anchor=H17#H17\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials\", section on 'Comparison to ACE inhibitor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    OPTIMAAL found a nonsignificant trend toward lower mortality at 2.7 years with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    (16.4 versus 18.2 percent, relative risk 0.88, 95% CI 0.78-1.01) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13175/abstract/14\">",
"     14",
"    </a>",
"    ], while VALIANT found no difference [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13175/abstract/15\">",
"     15",
"    </a>",
"    ]. We have a preference for ACE inhibitors based on the larger experience with ACE inhibitors in randomized trials and the much longer clinical experience with ACE inhibitors.",
"   </p>",
"   <p>",
"    For patients who are intolerant of ACE inhibitors, ARBs are recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ACE-I PLUS ARB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the VALIANT trial, an ARB therapy should not be given in addition to an ACE inhibitor in the immediate post-MI setting [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13175/abstract/15\">",
"     15",
"    </a>",
"    ]. At a median follow-up of 25 months, there was no difference among the three groups (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    , or both) in the primary end point of all cause mortality (19.9, 19.5, and 19.3 percent respectively). However, adverse events leading to a reduction in drug dose occurred more frequently with combination therapy than with either valsartan or captopril alone (34.8 versus 29.4 and 28.4 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=see_link&amp;anchor=H18#H18\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials\", section on 'Combination with ACE inhibitor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of combination therapy in symptomatic patients with chronic HF is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2680?source=see_link\">",
"     \"Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ASPIRIN AND ANGIOTENSIN INHIBITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    should be administered to all patients without a contraindication after an acute MI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There have been concerns that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    may reduce the overall benefit of ACE inhibitors. Such an interaction was suggested in a post hoc analysis from CONSENSUS-II, in which intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    was given very early after infarction, and in GUSTO-I and EPILOG, which were not trials evaluating ACE inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13175/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In contrast, no significant effect of aspirin on the benefit from ACE inhibition after acute MI was found in other trials or systematic reviews [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13175/abstract/3,18-20\">",
"     3,18-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although not randomized, the best available data in acute MI come from a review of almost 100,000 patients in large trials comparing ACE inhibitors to placebo during the acute phase of an MI [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13175/abstract/19\">",
"     19",
"    </a>",
"    ]. Patients treated with an ACE inhibitor and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (89 percent) had the same proportionate mortality benefit as those not taking aspirin.",
"   </p>",
"   <p>",
"    A direct comparison of ACE inhibitors with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is unlikely to be performed given the proven benefit of aspirin in patients who have had an MI. It may be prudent to use a maintenance aspirin dose of 75 to 150",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in patients with an acute MI who are concurrently treated with an ACE inhibitor; low dose aspirin appears to provide the same cardiovascular benefit as higher doses with less toxicity. This approach, while reasonable, has not been tested in prospective trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link&amp;anchor=H20#H20\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Dosing and cardiovascular benefit'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link&amp;anchor=H12#H12\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Secondary prevention of CVD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     BETA BLOCKERS AND ANGIOTENSIN INHIBITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concomitant use of beta blockers and angiotensin inhibitors is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=see_link&amp;anchor=H8#H8\">",
"     \"Beta blockers in the management of acute coronary syndrome\", section on 'LV dysfunction/heart failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of angiotensin converting enzyme inhibitor (ACE-I) or receptor blocker (ARB) to standard medical therapy (including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , thienopyridine, beta blocker, and statin) in patients with recent myocardial infarction improves cardiovascular outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/59/7098?source=see_link\">",
"     \"Overview of the non-acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=see_link\">",
"     \"Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefit is present in patients with either ST elevation or non-ST elevation MI. Evidence of benefit is somewhat stronger for patients with heart failure or less than normal left ventricular ejection fraction. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Evidence of benefit'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We recommend the addition of an ACE inhibitor or an ARB to standard medical therapy in patients with acute myocardial infarction who are at high risk (heart failure, a less than normal left ventricular ejection fraction, diabetes, or chronic kidney disease) of a subsequent cardiovascular event (",
"    <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"     Grade 1A",
"    </a>",
"    ). We suggest an ACE inhibitor rather than an ARB (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    We suggest the addition of an ACE inhibitor or an ARB to standard medical therapy in patients with acute myocardial infarction who are not at high risk (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). We suggest an ACE inhibitor rather than an ARB (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The following points should be considered in the use of these therapies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benefits have been shown with both early and late administration, with evidence for the former being stronger. We prefer starting therapy as early as possible. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Timing of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Irrespective of which agent and dose is chosen, the blood pressure must be monitored carefully to avoid hypotension. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest continuing therapy indefinitely (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13175/abstract/1\">",
"      Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation 1998; 97:2202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13175/abstract/2\">",
"      Pfeffer MA. ACE inhibition in acute myocardial infarction. N Engl J Med 1995; 332:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13175/abstract/3\">",
"      ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995; 345:669.",
"     </a>",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007). www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     Anderson J, Adams C, Antman E, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College or Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007; 50:e1 www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13175/abstract/6\">",
"      Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004; 110:e82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13175/abstract/7\">",
"      Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009; 54:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13175/abstract/8\">",
"      Frances CD, Noguchi H, Massie BM, et al. Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function. Arch Intern Med 2000; 160:2645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13175/abstract/9\">",
"      GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994; 343:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13175/abstract/10\">",
"      Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. J Am Coll Cardiol 1996; 27:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13175/abstract/11\">",
"      Latini R, Maggioni AP, Flather M, et al. ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation 1995; 92:3132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13175/abstract/12\">",
"      Rodrigues EJ, Eisenberg MJ, Pilote L. Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction. Am J Med 2003; 115:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13175/abstract/13\">",
"      Ruzicka M, Leenen FH. Relevance of blockade of cardiac and circulatory angiotensin-converting enzyme for the prevention of volume overload-induced cardiac hypertrophy. Circulation 1995; 91:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13175/abstract/14\">",
"      Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13175/abstract/15\">",
"      Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13175/abstract/16\">",
"      Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 1997; 79:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13175/abstract/17\">",
"      Peterson JG, Topol EJ, Sapp SK, et al. Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease. Am J Med 2000; 109:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13175/abstract/18\">",
"      Leor J, Reicher-Reiss H, Goldbourt U, et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease. J Am Coll Cardiol 1999; 33:1920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13175/abstract/19\">",
"      Latini R, Tognoni G, Maggioni AP, et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group. J Am Coll Cardiol 2000; 35:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13175/abstract/20\">",
"      Teo KK, Yusuf S, Pfeffer M, et al. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 2002; 360:1037.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 74 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-1745D172DA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_55_13175=[""].join("\n");
var outline_f12_55_13175=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVIDENCE OF BENEFIT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TIMING OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DOSING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DURATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ACE-I VERSUS ARB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ACE-I PLUS ARB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ASPIRIN AND ANGIOTENSIN INHIBITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      BETA BLOCKERS AND ANGIOTENSIN INHIBITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2680?source=related_link\">",
"      Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1799?source=related_link\">",
"      Angiotensin converting enzyme inhibitors in acute myocardial infarction: Mechanisms of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=related_link\">",
"      Beta blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20218?source=related_link\">",
"      Choice of therapy in essential hypertension: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=related_link\">",
"      Microalbuminuria in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/59/7098?source=related_link\">",
"      Overview of the non-acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=related_link\">",
"      Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_55_13176="Protein S deficiency";
var content_f12_55_13176=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Protein S deficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/55/13176/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/55/13176/contributors\">",
"     Kenneth A Bauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/55/13176/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/55/13176/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/55/13176/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/55/13176/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/55/13176/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/55/13176/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited thrombophilia is a genetic tendency to venous thromboembolism. The Factor V Leiden and prothrombin gene mutations are the most common causes of the syndrome accounting for more than 50 percent of cases. Deficiencies in protein S, protein C, and antithrombin account for most of the remaining cases, while rare causes include the dysfibrinogenemias [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The total incidence of an inherited thrombophilia in subjects with a deep vein thrombosis ranges from 24 to 37 percent overall compared with about 10 percent in controls. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Inherited thrombophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will discuss the genetics, prevalence, clinical presentation, and diagnosis of protein S deficiency. Issues related to screening for and the general treatment of the inherited thrombophilias are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=see_link\">",
"     \"Evaluation of the patient with established venous thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=see_link\">",
"     \"Screening for inherited thrombophilia in asymptomatic populations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=see_link\">",
"     \"Management of inherited thrombophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14234?source=see_link\">",
"     \"Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY OF PROTEIN S",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein S (PS), a vitamin K-dependent glycoprotein, is a cofactor of the protein C system. It was originally discovered and purified in Seattle, leading to the designation protein S. It is synthesized by both hepatocytes and megakaryocytes and circulates in two forms: 40 to 50 percent as the free form, and the remainder bound to the complement component, C4b-binding protein (C4b-BP); only the free form has activated protein C cofactor activity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the presence of PS, activated protein C inactivates factor Va and factor VIIIa at an increased rate, resulting in reduced thrombin generation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/5\">",
"     5",
"    </a>",
"    ]. PS also serves as a cofactor for protein C enhancement of fibrinolysis, and can directly inhibit prothrombin activation via interactions with other coagulation factors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/6-10\">",
"     6-10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENETICS OF PROTEIN S DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two homologous genes for PS map to chromosome 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The active gene, PROS1, spans over 80 kb and comprises 15 exons. The second gene, PROS2, has no open reading frames and is probably a pseudogene. The 5' part of the PROS1 gene shows strong homology with other vitamin K-dependent proteins. Exon 1 encodes the signal peptide, exon 4 a thrombin-sensitive loop, and exons 5 through 8 epidermal growth factor-like domains. The last seven exons (9 to 15), in the 3' part of the gene, encode a sex-hormone-binding globulin domain.",
"   </p>",
"   <p>",
"    Congenital protein S deficiency was first reported in 1984 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/13-15\">",
"     13-15",
"    </a>",
"    ] and has subsequently been described in numerous families [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/1,16-20\">",
"     1,16-20",
"    </a>",
"    ]. It is inherited predominantly as an autosomal dominant trait and heterozygous individuals in these families frequently had recurrent thromboembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/13\">",
"     13",
"    </a>",
"    ]. Severe thrombotic complications, including neonatal purpura fulminans, occur in the rare newborn with very low protein S levels, which is occasionally due to homozygous deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. However, homozygous protein S deficiency appears to be incompatible with life in man as well as in a mouse model of this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The large size of the PROS1 gene and the presence of the pseudogene have complicated the identification of gene mutations although an increasing number are being reported. Mutations have been identified in 70 percent of protein S deficient probands [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/25\">",
"     25",
"    </a>",
"    ] and a database of known protein S gene mutations has been published [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/26\">",
"     26",
"    </a>",
"    ]. Molecular analysis has identified only a few cases of large deletions of the protein S gene [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/25,27-29\">",
"     25,27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three phenotypes of PS deficiency have been defined on the basis of total PS concentrations, free PS concentrations, and activated protein C cofactor activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Type I",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic type of protein S deficiency is associated with approximately 50 percent of the normal total S antigen level, and more marked reductions in free protein S antigen and protein S functional activity (ie, a quantitative defect) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/15,16,30\">",
"     15,16,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among 69 candidate causal mutations identified in patients with the classic type of protein S deficiency, 51 percent are missense mutations, 25 percent are microinsertions or deletions of base pairs, 14 percent are premature stop codons, and 9 percent affect a splice site [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/30\">",
"     30",
"    </a>",
"    ]. Mutations in the protein S promoter have yet to be identified. It has been suggested that type I and type III, which is associated only with low free protein S antigen, are phenotypic variants of the same genetic disease (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Type II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type II protein S deficiency is characterized by normal total and free protein S levels, but diminished protein S functional activity (ie, a qualitative defect).",
"   </p>",
"   <p>",
"    This phenotype has been identified infrequently, which suggests that current functional assays may not screen for all such defects. All five mutations originally described in these patients were missense mutations located in the N-terminal end of the protein S molecule, which includes the domains that interact with activated protein C [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. These mutations may alter the conformation of protein S or interfere with carboxylation of the gamma-carboxyglutamic acid domain of the molecule [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Type III",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type III deficiency is characterized by total protein S antigen measurements in the normal range and selectively reduced levels of free protein S and protein S functional activity to less than approximately 40 percent of normal.",
"   </p>",
"   <p>",
"    While the mutations in type I protein S deficiency are distributed throughout the coding sequence, it has only been possible to identify protein S gene mutations in 44 percent of patients with the type III phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This observation raises the possibility that some cases of type III deficiency represent acquired abnormalities, such as aging, or are due to genetic factors linked to the mutation itself or to the genetic status of the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/26\">",
"     26",
"    </a>",
"    ]. The importance of type III deficiency is further complicated by reports in Swedish and Dutch thrombophilic families in which laboratory evaluation demonstrated the coexistence of the type I deficiency state and the low free protein S phenotype (ie, type III) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. These observations have led to the proposal that the two types of protein S deficiency may be phenotypic variants of the same genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/35,37,38\">",
"     35,37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among French patients with the low free protein S phenotype in which mutations could be identified, 82 percent had a single mutation leading to the replacement of Ser460 by Pro in the sex-hormone-binding globulin domain of protein S [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/39\">",
"     39",
"    </a>",
"    ]. The replacement was originally described as the Heerlen polymorphism and the mutation is also known as protein S Heerlen [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/40\">",
"     40",
"    </a>",
"    ]. The low free plasma protein S may result from increased binding of the abnormal protein S molecule to C4b-binding protein [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. It is not clear that the Ser460 to Pro mutation is associated with an increase in thrombotic risk since it has been identified with similar frequency in Dutch patients with thrombosis and in the general population (0.7 and 0.5 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Protein S Deficiency Database, patient phenotypes are described as quantitative (corresponding to types I or III) or qualitative (type II) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/26\">",
"     26",
"    </a>",
"    ]. Additional information on these mutations and their associated thrombotic risks can be obtained from the International Society on Thrombosis and Haemostasis (ISTH) website:",
"    <a class=\"external\" href=\"file://www.med.unc.edu/isth\">",
"     www.med.unc.edu/isth",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The prevalence of familial deficiency of protein S, estimated from a large cohort of healthy blood donors from the West of Scotland, is in the range of 0.03 to 0.13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of patients with heterozygous protein S deficiency is similar to that of antithrombin or protein C deficiency. Among 71 protein S-deficient members from 12 Dutch pedigrees, for example, 74, 72, and 38 percent of the individuals sustained deep venous thrombosis, superficial thrombophlebitis, or pulmonary embolism, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/19\">",
"     19",
"    </a>",
"    ]. The mean age of the first thrombotic event was 28 years with a range between 15 and 68 years; 56 percent of the episodes were apparently spontaneous and the remainder were precipitated by an identifiable factor.",
"   </p>",
"   <p>",
"    Thrombosis has also been reported in the axillary, mesenteric, and cerebral veins in patients with protein S deficiency, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -induced skin necrosis has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=see_link&amp;anchor=H13#H13\">",
"     \"Protein C deficiency\", section on 'Warfarin-induced skin necrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Deep vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thrombotic risk associated with protein S deficiency and other inherited thrombophilias has been assessed in two ways: evaluation of patients with deep vein thrombosis and evaluation of families with thrombophilia. In a Spanish study of 2132 consecutive unselected patients with venous thromboembolism, for example, 12.9 percent had an anticoagulant protein deficiency (7.3 percent with protein S, 3.2 percent with protein C, and 0.5 percent with antithrombin) and 4.1 percent had antiphospholipid antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/1\">",
"     1",
"    </a>",
"    ]. Similar findings were noted in a series of 277 Dutch outpatients with deep vein thrombosis: 8.3 percent had an isolated deficiency of antithrombin, protein C, protein S, or plasminogen compared with 2.2 percent of controls [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Inherited thrombophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The absolute risk of thrombosis among patients with inherited thrombophilia was evaluated in a report of 150 pedigrees which compared the risk for thrombosis in individuals with inherited thrombophilia due to factor V Leiden or to antithrombin, protein C, or protein S deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/20\">",
"     20",
"    </a>",
"    ]. The lifetime probability of developing thrombosis compared with those with no defect was 8.5 times higher for carriers of protein S deficiency, 8.1 for antithrombin deficiency, 7.3 for protein C deficiency, and 2.2 for factor V Leiden. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Inherited thrombophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In other studies of protein S deficient families with a high penetrance of thrombosis, the likelihood that affected family members remain thrombosis-free at 45 years of age has been reported to be 35 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/19,45\">",
"     19,45",
"    </a>",
"    ]. However, phenotypic studies are limited by the accuracy of the assays used and effects of age and sex. One study avoided these issues by studying the incidence of thrombosis in carriers in a family with a known missense mutation (Gly295Val) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/46\">",
"     46",
"    </a>",
"    ]. Little thrombotic risk was found before the age of 15 years. On the other hand, the likelihood of being free of thrombosis by age 30 was only 50 percent compared with 97 percent in normal family members. The odds ratio for thrombosis in affected subjects was 11.5. Measurement of total protein S antigen underestimated the risk for thromboembolism; in comparison, measurement of free protein S antigen levels was predictive of the mutation and deficiency. In another family study in which the diagnosis was established by genetic analysis, first-degree relatives with the PROS1 gene defect had a fivefold higher risk of thrombosis than those with a normal gene and no other apparent thrombophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients from families with thrombosis in association with deficiencies of protein S or protein C there appears to be an increased incidence of a second thrombotic defect, particularly factor V Leiden [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. In one series, factor V Leiden was present in 4 of 14 patients with protein S deficiency and 6 of 15 with protein C deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/49\">",
"     49",
"    </a>",
"    ]. Carriers of two defects seem to be at a higher risk for thrombosis than their relatives with a single defect. In one review of four studies, approximately 75 percent of the family members who were carriers of two defects had experienced thrombosis compared with 10 to 30 percent of the carriers of a single defect [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Arterial thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several case reports have described young patients with arterial thrombosis and hereditary protein S deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. However, larger studies have not convincingly demonstrated that protein S deficiency is a risk factor for the development of arterial thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. In one series, for example, antithrombin III, protein C, and protein S levels were measured in 127 consecutive patients with a mean age of 34 years admitted for an ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/54\">",
"     54",
"    </a>",
"    ]. Abnormal anticoagulant protein levels were found in nine patients. However, seven of these patients had an acquired cause of deficiency, such as pregnancy or estrogen administration, and the other two patients had transiently low levels in the absence of an obvious acquired cause. Similar findings were noted in another study of 120 young patients with stroke: 20 had decreased protein S levels at initial evaluation, a change that persisted in only two at second measurement [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein S deficiency is the most difficult of the hereditary thrombophilias to document with certainty. Free protein S is probably the best screening test [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/46\">",
"     46",
"    </a>",
"    ], although many use the functional protein S assay, which has a larger coefficient of variation and occasional false positives when the factor V Leiden mutation is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Total protein S",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total protein S antigen is measured by various types of immunoassay techniques. These tests generally involve dilution of plasma samples, which favors dissociation of the protein S-C4b-binding protein complexes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Free protein S",
"    </span>",
"    &nbsp;&mdash;&nbsp;Original free protein S assays used polyethylene glycol precipitation to remove protein S-C4b-binding protein complexes from plasma; free protein S was then measured by immunoassay of the supernatant fractions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/41\">",
"     41",
"    </a>",
"    ]. It is now possible to measure free protein S specifically using monoclonal antibody-based assays and ligand sorbent assays, which eliminate the PEG precipitation step [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/30,57-59\">",
"     30,57-59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Functional assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional assay methods are based upon the ability of protein S to serve as a cofactor for the anticoagulant effect of activated protein C [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. However, some of these assays are not specific for protein S since they are also sensitive to the defect characterized by resistance to activated protein C. As a result, their use can lead to an erroneous diagnosis of functional protein S deficiency in a patient with other causes of activated protein C resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/62\">",
"     62",
"    </a>",
"    ]. A strategy of first screening plasma samples for APC resistance prior to performance of functional protein S assays can obviate this potential problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Plasma concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The average plasma concentration of total protein S antigen in normal adults is 23",
"    <span class=\"nowrap\">",
"     microg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/63\">",
"     63",
"    </a>",
"    ]. Levels increase with advancing age and are significantly lower and more variable in females than males [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/37,64\">",
"     37,64",
"    </a>",
"    ]. The increase with age is seen with total protein S but not free protein S; the latter finding is explained by an association between beta-chain containing C4b-binding protein antigen levels and age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one series of 150 patients, plasma total protein S antigen concentration was associated with serum total cholesterol, rising 10 percent as total cholesterol increased from the 5th to the 95th percentile [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/65\">",
"     65",
"    </a>",
"    ]. A similar rise in triglycerides was associated with an even larger increase in mean free protein S antigen.",
"   </p>",
"   <p>",
"    The range in protein S levels in the normal population is wider than that for protein C or antithrombin. Additionally, functional protein S assays have a higher coefficient of variation than antigenic assays. In practice, it is therefore necessary to perform repeat testing and perform family studies to firmly establish the diagnosis of hereditary protein S deficiency.",
"   </p>",
"   <p>",
"    In general, levels of total or free protein S antigen &lt;60 to 65",
"    <span class=\"nowrap\">",
"     IU/dL",
"    </span>",
"    are considered to be in the deficient range [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/66\">",
"     66",
"    </a>",
"    ]. However, in a prospective family cohort study involving 1143 relatives with various thrombophilic defects, only young relatives with free protein S levels less than the 5th percentile (&lt;41",
"    <span class=\"nowrap\">",
"     IU/dL)",
"    </span>",
"    or less than the 2.5th percentile (&lt;33",
"    <span class=\"nowrap\">",
"     IU/dL)",
"    </span>",
"    were at higher risk of a first venous thrombosis compared with those in the upper quartile (&gt;91",
"    <span class=\"nowrap\">",
"     IU/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Timing of screening and effect of warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important consideration in the laboratory evaluation of patients with a suspected deficiency of antithrombin, protein C, or protein S is the timing of testing. Erroneous diagnoses can be made due to the influence of acute thrombosis, comorbid illness, or anticoagulant therapy on the concentrations of these plasma proteins. Interpretation of protein S measurements is particularly difficult in individuals treated with oral anticoagulants, which substantially lower both antigenic and functional levels of the protein. It has been proposed that a reduction in the ratio of protein S antigen to prothrombin antigen can be used to infer a diagnosis of the classic type of protein S deficiency state in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In practice, it is preferable to investigate patients suspected of having protein S (or protein C) deficiency after oral anticoagulation has been discontinued for at least two weeks and to perform family studies. If it is not possible to discontinue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    due to the severity of the thrombotic diathesis, such individuals can be studied while receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy, which does not alter plasma protein S concentrations.",
"   </p>",
"   <p>",
"    If, however, plasma levels of protein S are obtained at presentation and are well within the normal range, then a deficiency of this protein is essentially excluded. A low concentration, on the other hand, must be confirmed by repeat testing after anticoagulation is discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Newborns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total protein S antigen values in healthy newborns at term are 15 to 30 percent of normal while C4b-binding protein is markedly reduced to less than 20 percent. Thus, the free form of the protein predominates in this setting and functional levels are only slightly reduced as compared with those in normal adults [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/67\">",
"     67",
"    </a>",
"    ]. As methodologies for measurement of protein S differ among laboratories and the concentration is substantially lower in normal newborns and young infants compared with adult values, it is important to use age-based norms for the specific laboratory performing the test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Acquired protein S deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired protein S deficiency occurs during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/68\">",
"     68",
"    </a>",
"    ] and in association with the use of oral contraceptives [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/64,69\">",
"     64,69",
"    </a>",
"    ]. Reduced protein S levels have also been noted in a variety of other disorders. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disseminated intravascular coagulation [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/70,71\">",
"       70,71",
"      </a>",
"      ] and acute thromboembolic disease [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/71\">",
"       71",
"      </a>",
"      ]. C4b-binding protein is an acute phase protein; as a result, the declines in protein S activity in the latter two conditions and in other inflammatory disorders is attributable to a shift of the protein to the complexed, inactive form [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HIV infection in which total and especially free protein S are significantly reduced [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The nephrotic syndrome, which is generally characterized by increased total protein S antigen but reduced protein S functional assays [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/73,74\">",
"       73,74",
"      </a>",
"      ]. This pattern is in part due to the loss of free protein S in the urine and an elevation in plasma C4b-binding protein concentrations.",
"     </li>",
"     <li>",
"      Total and free protein S antigen are moderately decreased in liver disease [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/41,69\">",
"       41,69",
"      </a>",
"      ] and in association with L-asparaginase chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/75\">",
"       75",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/36/6730?source=see_link\">",
"       \"Drug-induced thrombosis and vascular disease in patients with malignancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a patient with thromboembolic disease recovering from chickenpox, a transient isolated deficiency of protein S was induced by an autoantibody directed against this protein [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13176/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26779752\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein S (PS), a vitamin K-dependent glycoprotein, is a cofactor for activated protein C (aPC). It is synthesized by hepatocytes and megakaryocytes; 40 to 50 percent circulates as the free form; only the free form has aPC cofactor activity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Function",
"      </strong>",
"      &mdash; In the presence of PS, aPC inactivates factor Va and factor VIIIa at an increased rate. PS is also a cofactor for protein C enhancement of fibrinolysis, and can directly inhibit prothrombin activation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Physiology of protein S'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Genetics",
"      </strong>",
"      &mdash; PS deficiency is an autosomal dominant trait. Homozygous PS deficiency is incompatible with life. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Genetics of protein s deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Clinical manifestations",
"      </strong>",
"      &mdash; The clinical presentation of PS deficiency includes deep venous thrombosis, superficial thrombophlebitis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pulmonary embolism. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Diagnosis",
"      </strong>",
"      &mdash; Levels of total or free PS antigen &lt;60 to 65 International",
"      <span class=\"nowrap\">",
"       units/dL",
"      </span>",
"      are considered to be in the deficient range. Erroneous diagnoses can be made due to the influence of acute thrombosis, comorbid illness, during pregnancy, and in association with the use of oral contraceptives or vitamin K antagonists. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Acquired protein S deficiency'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/1\">",
"      Mateo J, Oliver A, Borrell M, et al. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost 1997; 77:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/2\">",
"      Margaglione M, Brancaccio V, Giuliani N, et al. Increased risk for venous thrombosis in carriers of the prothrombin G--&gt;A20210 gene variant. Ann Intern Med 1998; 129:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/3\">",
"      Leroy-Matheron C, Gouault-Heilmann M, Aiach M, Gandrille S. A mutation of the active protein S gene leading to an EGF1-lacking protein in a family with qualitative (type II) deficiency. Blood 1998; 91:4608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/4\">",
"      Rezende SM, Simmonds RE, Lane DA. Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex. Blood 2004; 103:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/5\">",
"      Esmon CT. Protein S and protein C Biochemistry, physiology, and clinical manifestation of deficiencies. Trends Cardiovasc Med 1992; 2:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/6\">",
"      Dahlb&auml;ck B. The protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thromb Res 1995; 77:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/7\">",
"      Koppelman SJ, Hackeng TM, Sixma JJ, Bouma BN. Inhibition of the intrinsic factor X activating complex by protein S: evidence for a specific binding of protein S to factor VIII. Blood 1995; 86:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/8\">",
"      Hackeng TM, van 't Veer C, Meijers JC, Bouma BN. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem 1994; 269:21051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/9\">",
"      Koenen RR, Tans G, van Oerle R, et al. The APC-independent anticoagulant activity of protein S in plasma is decreased by elevated prothrombin levels due to the prothrombin G20210A mutation. Blood 2003; 102:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/10\">",
"      Takeyama M, Nogami K, Saenko EL, et al. Protein S down-regulates factor Xase activity independent of activated protein C: specific binding of factor VIII(a) to protein S inhibits interactions with factor IXa. Br J Haematol 2008; 143:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/11\">",
"      Ploos van Amstel JK, van der Zanden AL, Bakker E, et al. Two genes homologous with human protein S cDNA are located on chromosome 3. Thromb Haemost 1987; 58:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/12\">",
"      Schmidel DK, Tatro AV, Phelps LG, et al. Organization of the human protein S genes. Biochemistry 1990; 29:7845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/13\">",
"      Comp PC, Nixon RR, Cooper MR, Esmon CT. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984; 74:2082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/14\">",
"      Comp PC, Esmon CT. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 1984; 311:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/15\">",
"      Schwarz HP, Fischer M, Hopmeier P, et al. Plasma protein S deficiency in familial thrombotic disease. Blood 1984; 64:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/16\">",
"      Broekmans AW, Bertina RM, Reinalda-Poot J, et al. Hereditary protein S deficiency and venous thrombo-embolism. A study in three Dutch families. Thromb Haemost 1985; 53:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/17\">",
"      Heijboer H, Brandjes DP, B&uuml;ller HR, et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/18\">",
"      Tabernero MD, Tomas JF, Alberca I, et al. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol 1991; 36:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/19\">",
"      Engesser L, Broekmans AW, Bri&euml;t E, et al. Hereditary protein S deficiency: clinical manifestations. Ann Intern Med 1987; 106:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/20\">",
"      Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92:2353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/21\">",
"      Mahasandana C, Suvatte V, Marlar RA, et al. Neonatal purpura fulminans associated with homozygous protein S deficiency. Lancet 1990; 335:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/22\">",
"      G&oacute;mez E, Ledford MR, Pegelow CH, et al. Homozygous protein S deficiency due to a one base pair deletion that leads to a stop codon in exon III of the protein S gene. Thromb Haemost 1994; 71:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/23\">",
"      Saller F, Brisset AC, Tchaikovski SN, et al. Generation and phenotypic analysis of protein S-deficient mice. Blood 2009; 114:2307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/24\">",
"      Burstyn-Cohen T, Heeb MJ, Lemke G. Lack of protein S in mice causes embryonic lethal coagulopathy and vascular dysgenesis. J Clin Invest 2009; 119:2942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/25\">",
"      Borgel D, Gandrille S, Aiach M. Protein S deficiency. Thromb Haemost 1997; 78:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/26\">",
"      Gandrille S, Borgel D, Sala N, et al. Protein S deficiency: a database of mutations--summary of the first update. Thromb Haemost 2000; 84:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/27\">",
"      Ploos van Amstel HK, Huisman MV, Reitsma PH, et al. Partial protein S gene deletion in a family with hereditary thrombophilia. Blood 1989; 73:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/28\">",
"      Schmidel DK, Nelson RM, Broxson EH Jr, et al. A 5.3-kb deletion including exon XIII of the protein S alpha gene occurs in two protein S-deficient families. Blood 1991; 77:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/29\">",
"      Holmes ZR, Bertina RM, Reitsma PH. Characterization of a large chromosomal deletion in the PROS1 gene of a patient with protein S deficiency type I using long PCR. Br J Haematol 1996; 92:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/30\">",
"      Amiral J, Grosley B, Boyer-Neumann C, et al. New direct assay of free protein S antigen using two distinct monoclonal antibodies specific for the free form. Blood Coagul Fibrinolysis 1994; 5:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/31\">",
"      Gandrille S, Borgel D, Eschwege-Gufflet V, et al. Identification of 15 different candidate causal point mutations and three polymorphisms in 19 patients with protein S deficiency using a scanning method for the analysis of the protein S active gene. Blood 1995; 85:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/32\">",
"      Simmonds RE, Ireland H, Kunz G, Lane DA. Identification of 19 protein S gene mutations in patients with phenotypic protein S deficiency and thrombosis. Protein S Study Group. Blood 1996; 88:4195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/33\">",
"      Shigekiyo T, Uno Y, Kawauchi S, et al. Protein S Tokushima: an abnormal protein S found in a Japanese family with thrombosis. Thromb Haemost 1993; 70:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/34\">",
"      Hayashi T, Nishioka J, Shigekiyo T, et al. Protein S Tokushima: abnormal molecule with a substitution of Glu for Lys-155 in the second epidermal growth factor-like domain of protein S. Blood 1994; 83:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/35\">",
"      Z&ouml;ller B, Garc&iacute;a de Frutos P, Dahlb&auml;ck B. Evaluation of the relationship between protein S and C4b-binding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease. Blood 1995; 85:3524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/36\">",
"      Brouwer JL, Veeger NJ, van der Schaaf W, et al. Difference in absolute risk of venous and arterial thrombosis between familial protein S deficiency type I and type III. Results from a family cohort study to assess the clinical impact of a laboratory test-based classification. Br J Haematol 2005; 128:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/37\">",
"      Simmonds RE, Z&ouml;ller B, Ireland H, et al. Genetic and phenotypic analysis of a large (122-member) protein S-deficient kindred provides an explanation for the familial coexistence of type I and type III plasma phenotypes. Blood 1997; 89:4364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/38\">",
"      Andersen BD, Bisgaard ML, Lind B, et al. Characterization and structural impact of five novel PROS1 mutations in eleven protein S-deficient families. Thromb Haemost 2001; 86:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/39\">",
"      Borgel D, Duchemin J, Alhenc-Gelas M, et al. Molecular basis for protein S hereditary deficiency: genetic defects observed in 118 patients with type I and type IIa deficiencies. The French Network on Molecular Abnormalities Responsible for Protein C and Protein S Deficiencies. J Lab Clin Med 1996; 128:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/40\">",
"      Bertina RM, Ploos van Amstel HK, van Wijngaarden A, et al. Heerlen polymorphism of protein S, an immunologic polymorphism due to dimorphism of residue 460. Blood 1990; 76:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/41\">",
"      Comp PC, Doray D, Patton D, Esmon CT. An abnormal plasma distribution of protein S occurs in functional protein S deficiency. Blood 1986; 67:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/42\">",
"      Duchemin J, Gandrille S, Borgel D, et al. The Ser 460 to Pro substitution of the protein S alpha (PROS1) gene is a frequent mutation associated with free protein S (type IIa) deficiency. Blood 1995; 86:3436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/43\">",
"      Dykes AC, Walker ID, McMahon AD, et al. A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol 2001; 113:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/44\">",
"      Sallah S, Abdallah JM, Gagnon GA. Recurrent warfarin-induced skin necrosis in kindreds with protein S deficiency. Haemostasis 1998; 28:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/45\">",
"      Z&ouml;ller B, Berntsdotter A, Garc&iacute;a de Frutos P, Dahlb&auml;ck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85:3518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/46\">",
"      Simmonds RE, Ireland H, Lane DA, et al. Clarification of the risk for venous thrombosis associated with hereditary protein S deficiency by investigation of a large kindred with a characterized gene defect. Ann Intern Med 1998; 128:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/47\">",
"      Makris M, Leach M, Beauchamp NJ, et al. Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S. Blood 2000; 95:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/48\">",
"      Koeleman BP, Reitsma PH, Bertina RM. Familial thrombophilia: a complex genetic disorder. Semin Hematol 1997; 34:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/49\">",
"      Mustafa S, Mannhalter C, Rintelen C, et al. Clinical features of thrombophilia in families with gene defects in protein C or protein S combined with factor V Leiden. Blood Coagul Fibrinolysis 1998; 9:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/50\">",
"      Coller BS, Owen J, Jesty J, et al. Deficiency of plasma protein S, protein C, or antithrombin III and arterial thrombosis. Arteriosclerosis 1987; 7:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/51\">",
"      Girolami A, Simioni P, Lazzaro AR, Cordiano I. Severe arterial cerebral thrombosis in a patient with protein S deficiency (moderately reduced total and markedly reduced free protein S): a family study. Thromb Haemost 1989; 61:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/52\">",
"      Green D, Otoya J, Oriba H, Rovner R. Protein S deficiency in middle-aged women with stroke. Neurology 1992; 42:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/53\">",
"      Allaart CF, Aronson DC, Ruys T, et al. Hereditary protein S deficiency in young adults with arterial occlusive disease. Thromb Haemost 1990; 64:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/54\">",
"      Douay X, Lucas C, Caron C, et al. Antithrombin, protein C and protein S levels in 127 consecutive young adults with ischemic stroke. Acta Neurol Scand 1998; 98:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/55\">",
"      Munts AG, van Genderen PJ, Dippel DW, et al. Coagulation disorders in young adults with acute cerebral ischaemia. J Neurol 1998; 245:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/56\">",
"      Bertina RM, van Wijngaarden A, Reinalda-Poot J, et al. Determination of plasma protein S--the protein cofactor of activated protein C. Thromb Haemost 1985; 53:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/57\">",
"      Gardiner C, Mackie IJ, Machin SJ. Simultaneous assay of free and total protein S by ELISA using monoclonal and polyclonal antibodies. Clin Lab Haematol 1998; 20:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/58\">",
"      Ravanat C, Wiesel ML, Schuhler S, et al. One-step assay for the determination of free protein S antigen in plasma using real-time biospecific interaction analysis. Blood Coagul Fibrinolysis 1998; 9:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/59\">",
"      Giri TK, Hillarp A, H&auml;rdig Y, et al. A new direct, fast and quantitative enzyme-linked ligandsorbent assay for measurement of free protein S antigen. Thromb Haemost 1998; 79:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/60\">",
"      Wolf M, Boyer-Neumann C, Martinoli JL, et al. A new functional assay for human protein S activity using activated factor V as substrate. Thromb Haemost 1989; 62:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/61\">",
"      Preda L, Tripodi A, Valsecchi C, et al. A prothrombin time-based functional assay of protein S. Thromb Res 1990; 60:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/62\">",
"      Faioni EM, Franchi F, Asti D, et al. Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay. Thromb Haemost 1993; 70:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/63\">",
"      Fair DS, Revak DJ. Quantitation of human protein S in the plasma of normal and warfarin-treated individuals by radioimmunoassay. Thromb Res 1984; 36:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/64\">",
"      Boerger LM, Morris PC, Thurnau GR, et al. Oral contraceptives and gender affect protein S status. Blood 1987; 69:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/65\">",
"      MacCallum PK, Cooper JA, Martin J, et al. Associations of protein C and protein S with serum lipid concentrations. Br J Haematol 1998; 102:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/66\">",
"      Lijfering WM, Mulder R, ten Kate MK, et al. Clinical relevance of decreased free protein S levels: results from a retrospective family cohort study involving 1143 relatives. Blood 2009; 113:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/67\">",
"      Schwarz HP, Muntean W, Watzke H, et al. Low total protein S antigen but high protein S activity due to decreased C4b-binding protein in neonates. Blood 1988; 71:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/68\">",
"      Comp PC, Thurnau GR, Welsh J, Esmon CT. Functional and immunologic protein S levels are decreased during pregnancy. Blood 1986; 68:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/69\">",
"      Gilabert J, Fernandez JA, Espa&ntilde;a F, et al. Physiological coagulation inhibitors (protein S, protein C and antithrombin III) in severe preeclamptic states and in users of oral contraceptives. Thromb Res 1988; 49:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/70\">",
"      Heeb MJ, Mosher D, Griffin JH. Activation and complexation of protein C and cleavage and decrease of protein S in plasma of patients with intravascular coagulation. Blood 1989; 73:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/71\">",
"      D'Angelo A, Vigano-D'Angelo S, Esmon CT, Comp PC. Acquired deficiencies of protein S. Protein S activity during oral anticoagulation, in liver disease, and in disseminated intravascular coagulation. J Clin Invest 1988; 81:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/72\">",
"      Stahl CP, Wideman CS, Spira TJ, et al. Protein S deficiency in men with long-term human immunodeficiency virus infection. Blood 1993; 81:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/73\">",
"      Vigano-D'Angelo S, D'Angelo A, Kaufman CE Jr, et al. Protein S deficiency occurs in the nephrotic syndrome. Ann Intern Med 1987; 107:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/74\">",
"      Gouault-Heilmann M, Gadelha-Parente T, Levent M, et al. Total and free protein S in nephrotic syndrome. Thromb Res 1988; 49:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/75\">",
"      Pui CH, Chesney CM, Bergum PW, et al. Lack of pathogenetic role of proteins C and S in thrombosis associated with asparaginase-prednisone-vincristine therapy for leukaemia. Br J Haematol 1986; 64:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13176/abstract/76\">",
"      D'Angelo A, Della Valle P, Crippa L, et al. Brief report: autoimmune protein S deficiency in a boy with severe thromboembolic disease. N Engl J Med 1993; 328:1753.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1357 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.65.66-BC5B390E05-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_55_13176=[""].join("\n");
var outline_f12_55_13176=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26779752\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSIOLOGY OF PROTEIN S",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENETICS OF PROTEIN S DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Type I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Type II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Type III",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Arterial thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Total protein S",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Free protein S",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Functional assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Plasma concentration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Timing of screening and effect of warfarin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Newborns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Acquired protein S deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26779752\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14234?source=related_link\">",
"      Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/36/6730?source=related_link\">",
"      Drug-induced thrombosis and vascular disease in patients with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=related_link\">",
"      Management of inherited thrombophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=related_link\">",
"      Screening for inherited thrombophilia in asymptomatic populations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_55_13177="Inborn errors of metabolism: Identifying the specific disorder";
var content_f12_55_13177=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Inborn errors of metabolism: Identifying the specific disorder",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/55/13177/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/55/13177/contributors\">",
"     V Reid Sutton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/55/13177/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/55/13177/contributors\">",
"     Sihoun Hahn, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/55/13177/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/55/13177/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/55/13177/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/55/13177/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H5818513\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital metabolic disorders result from the absence or abnormality of an enzyme or its cofactor, leading to either accumulation or deficiency of a specific metabolite (",
"    <a class=\"graphic graphic_table graphicRef82924 \" href=\"UTD.htm?39/44/40651\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef56040 \" href=\"UTD.htm?8/23/8572\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef69937 \" href=\"UTD.htm?8/13/8411\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74261 \" href=\"UTD.htm?21/62/22507\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63392 \" href=\"UTD.htm?7/60/8140\">",
"     table 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef86411 \" href=\"UTD.htm?24/12/24780\">",
"     table 6",
"    </a>",
"    ). Optimal outcome for children with inborn errors of metabolism (IEM) depends upon recognition of the signs and symptoms of metabolic disease, prompt evaluation, and referral to a center familiar with the evaluation and management of these disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13177/abstract/1\">",
"     1",
"    </a>",
"    ]. Delay in diagnosis may result in acute metabolic decompensation, progressive neurologic injury, or death.",
"   </p>",
"   <p>",
"    This topic provides an overview of the evaluation for children with suspected IEM. Confirmation of diagnosis of specific disorders typically requires specialized testing and should be undertaken in consultation with a specialist in genetics or metabolic diseases. The classification, most common presentations, and initial evaluation and management of IEM, particularly those that present as metabolic emergencies, are discussed separately, as are individual disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27047?source=see_link\">",
"     \"Inborn errors of metabolism: Classification\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2926302\">",
"    <span class=\"h1\">",
"     NEWBORN SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A newborn may present with a positive newborn screen for IEM before clinical manifestations are present or recognized. Newborn screening programs screen all newborns for a specific set of IEM [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13177/abstract/2\">",
"     2",
"    </a>",
"    ]. The testing methods and disorders that are screened vary from state to state and country to country. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2088?source=see_link\">",
"     \"Newborn screening\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Newborn screening programs increase the detection of IEM, but cannot be relied upon exclusively. False-positive and false-negative screening tests occur, usually as a result of screening too early (ie, before adequate \"challenge\" with protein or carbohydrate), medications,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13177/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, the results of the screening tests may not be available in the first few days of life, when some IEM may present. Furthermore, newborn screening programs do not screen for all IEM. As an example, the urea cycle disorders ornithine transcarbamylase deficiency and carbamylphosphate synthetase deficiency are not detected by available newborn screening methods. Improved detection depends upon a high index of suspicion. Guidelines for evaluation following an abnormal newborn screen can be found in",
"    <a class=\"external\" href=\"file://www.acmg.net/AM/Template.cfm?Section=ACT_Sheets_and_Confirmatory_Algorithms&amp;Template=/CM/HTMLDisplay.cfm&amp;ContentID=5661\">",
"     ACTion (ACT) sheets from the American College of Medical Genetics",
"    </a>",
"    . These guidelines and other helpful information are also often available from the state newborn screening program (including postings on their websites). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2088?source=see_link\">",
"     \"Newborn screening\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12033749\">",
"    <span class=\"h1\">",
"     CLINICAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history should focus on previous episodes of metabolic decompensation, identification of potential triggering events, and family history of metabolic disease or members with similar presentations.",
"   </p>",
"   <p>",
"    The clinician should be mindful that while many &ldquo;classic&rdquo; presentations of inborn errors of metabolism occur in infancy, almost all metabolic disorders can have later-onset presentations, including late adulthood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12033756\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The perinatal history for many common inborn errors of metabolism (IEM), including urea cycle disorders, and most aminoacidopathies and organic acidemias, is usually normal since impaired metabolism in the fetus is generally well-compensated for by the mother.",
"   </p>",
"   <p>",
"    However, in certain disorders there may be problems with the pregnancy and abnormalities at birth. These disorders include, but are not limited to, nonketotic hyperglycinemia, peroxisomal disorders, some lysosomal storage disorders, and disorders of cholesterol biosynthesis. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low maternal serum estriol can be found on routine maternal serum screening in pregnancies affected with Smith-Lemli-Opitz syndrome, isolated steroid sulfatase deficiency (X-linked ichthyosis), and multiple sulfatase deficiency.",
"     </li>",
"     <li>",
"      Decreased fetal movement may be seen, particularly in Smith-Lemli-Opitz syndrome, glycogen storage disease type IV (glycogen branching enzyme deficiency), certain lysosomal storage diseases, and peroxisomal disorders, such as Zellweger syndrome.",
"     </li>",
"     <li>",
"      The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count), acute fatty liver of pregnancy (AFLP), and hyperemesis are associated with long-chain 3-hydroxyacly-CoA dehydrogenase deficiency (albeit rarely) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13177/abstract/4-6\">",
"       4-6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Steroid sulfatase deficiency can cause prolonged labor as a result of decreased placental estrogen production [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13177/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Numerous IEM are associated with nonimmune hydrops (",
"      <a class=\"graphic graphic_table graphicRef57407 \" href=\"UTD.htm?24/50/25387\">",
"       table 7",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=see_link\">",
"       \"Nonimmune hydrops fetalis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link&amp;anchor=H26#H26\">",
"       \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\", section on 'Hydrops fetalis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The past medical history should include questions regarding (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link&amp;anchor=H16728975#H16728975\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\", section on 'Clinical presentations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link&amp;anchor=H3681940#H3681940\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\", section on 'Laboratory findings'",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13177/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent vomiting (in some cases the child may have been diagnosed with formula intolerance or pyloric stenosis during infancy, so it is important to ask about these entities specifically)",
"     </li>",
"     <li>",
"      Hospitalization for lethargy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dehydration with rapid response to infusion of intravenous (IV) fluid or glucose",
"     </li>",
"     <li>",
"      Recurrent hypoglycemia",
"     </li>",
"     <li>",
"      Metabolic decompensation out of proportion to duration or severity of acute illness",
"     </li>",
"     <li>",
"      A personal or family history of thrombotic events (suggestive of homocystinuria)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The review of systems should include questions regarding [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13177/abstract/10,12-15\">",
"     10,12-15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Episodic abdominal pain, which may occur in Fabry disease and the hepatic porphyrias [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13177/abstract/12,13,15\">",
"       12,13,15",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40137?source=see_link\">",
"       \"Clinical features and diagnosis of Fabry disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10439?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute intermittent porphyria\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Photophobia, an indication of corneal scarring that may occur in cystinosis and tyrosinemia type II [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13177/abstract/14\">",
"       14",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12584?source=see_link\">",
"       \"Cystinosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23624?source=see_link\">",
"       \"Disorders of tyrosine metabolism\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Muscle cramping after exercise, suggesting fatty acid oxidation defects, muscle glycogenoses and other glycogen storage diseases (GSD), or myoadenylate deaminase deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13177/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Developmental delay, with or without loss of milestones",
"     </li>",
"     <li>",
"      Lethargy in the morning (after an overnight fast) or with delayed feeding",
"     </li>",
"     <li>",
"      Poor feeding, frequent vomiting",
"     </li>",
"     <li>",
"      Poor",
"      <span class=\"nowrap\">",
"       growth/failure",
"      </span>",
"      to thrive",
"     </li>",
"     <li>",
"      Protein or carbohydrate aversion",
"     </li>",
"     <li>",
"      Diarrhea, which may be a feature of carbohydrate intolerance or mitochondrial disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several IEM are triggered by specific circumstances. It is important to ask about the following triggers in the evaluation of a child with suspected IEM [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13177/abstract/10,16\">",
"     10,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ingestion of certain sugars may trigger disorders of carbohydrate intolerance (ie, galactosemia, hereditary fructose intolerance). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30886?source=see_link\">",
"       \"Clinical features and diagnosis of galactosemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16010?source=see_link&amp;anchor=H15#H15\">",
"       \"Etiology of hypoglycemia in infants and children\", section on 'Hereditary fructose intolerance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ingestion of protein may trigger urea cycle defects, organic acidemias, amino acid disorders, and hyperinsulinism with hyperammonemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20248?source=see_link\">",
"       \"Urea cycle disorders: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=see_link\">",
"       \"Organic acidemias\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3866?source=see_link&amp;anchor=H7#H7\">",
"       \"Pathogenesis, clinical features, and diagnosis of persistent hyperinsulinemic hypoglycemia of infancy\", section on 'Glutamate dehydrogenase defects'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ingestion of carbohydrate may trigger pyruvate dehydrogenase deficiency, mitochondrial respiratory chain disorders, or hyperinsulinism.",
"     </li>",
"     <li>",
"      The introduction of complementary foods (eg, infant cereals, fruit juice, and pureed fruits, vegetables, or meats) to the infant diet may trigger disorders of carbohydrate metabolism, urea cycle defects, and organic acidemias.",
"     </li>",
"     <li>",
"      Infection, fever, fasting, or catabolism may trigger amino acid disorders, organic acidemias, fatty acid oxidation disorders, urea cycle defects, and disorders of gluconeogenesis and glycogenolysis.",
"     </li>",
"     <li>",
"      Anesthesia or surgery may trigger thromboembolic events in homocystinuria in addition to the disorders triggered by fasting described above.",
"     </li>",
"     <li>",
"      Certain drugs may trigger porphyria (",
"      <a class=\"graphic graphic_table graphicRef57422 \" href=\"UTD.htm?42/6/43116\">",
"       table 8",
"      </a>",
"      ) and glucose-6-phosphate dehydrogenase deficiency (",
"      <a class=\"graphic graphic_table graphicRef74254 \" href=\"UTD.htm?19/22/19821\">",
"       table 9",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The family history should include a three-generation pedigree and questions regarding [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13177/abstract/4,11,15,17\">",
"     4,11,15,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Consanguinity (most of the disorders have autosomal recessive inheritance, although some, such as ornithine transcarbamylase deficiency, Hunter syndrome, X-linked adrenoleukodystrophy, and creatine transporter deficiency, are X-linked (",
"      <a class=\"graphic graphic_figure graphicRef80586 \" href=\"UTD.htm?2/7/2174\">",
"       figure 1",
"      </a>",
"      ) and some, such as MELAS [mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes], MERFF [myoclonic epilepsy with ragged red fibers], and NARP [neuropathy, ataxia, and retinitis pigmentosa], have a mitochondrial [maternal] inheritance pattern (",
"      <a class=\"graphic graphic_figure graphicRef79033 \" href=\"UTD.htm?2/53/2910\">",
"       figure 2",
"      </a>",
"      )).",
"     </li>",
"     <li>",
"      Similarly affected individuals (the absence of such a history does not exclude IEM since most are autosomal recessive and only affected siblings would be likely).",
"     </li>",
"     <li>",
"      Early childhood deaths due to neurologic, cardiac,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hepatic dysfunction; sepsis, or unexplained deaths in siblings or maternal male relatives (the absence of such a history does not exclude IEM since most are autosomal recessive and the recurrence risk is 25 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12033797\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination of infants and children with IEM may be normal [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13177/abstract/11\">",
"     11",
"    </a>",
"    ], demonstrate nonspecific findings, or provide clues to specific disorders. The disorders associated with selected examination findings are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef51536 \" href=\"UTD.htm?11/26/11694\">",
"     table 10",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link&amp;anchor=H4#H4\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12033830\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest a stepwise approach to evaluation, beginning with basic tests that are routinely available [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13177/abstract/8-11,14,16\">",
"     8-11,14,16",
"    </a>",
"    ], before completing specialized metabolic investigations (",
"    <a class=\"graphic graphic_table graphicRef67745 \" href=\"UTD.htm?1/63/2045\">",
"     table 11",
"    </a>",
"    ). The confirmatory diagnosis of most IEMs requires specialized testing that may include detection of abnormal metabolites in the plasma, urine,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cerebrospinal fluid (CSF); assay of enzyme activity in skin, red blood cells, white blood cells, skeletal muscle, or liver;",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chromosome or DNA analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13177/abstract/10\">",
"     10",
"    </a>",
"    ]. Decisions regarding specialized testing are best undertaken in consultation with a specialist in genetics or metabolic disorders and laboratory personnel to make sure that specimens are obtained, processed, and analyzed appropriately [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13177/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ordering clinician should know the method used to perform the analyses so that the results can be correctly interpreted. As an example, quantitative amino acid analysis is more reliable than is qualitative analysis using paper chromatography to identify specific disorders, as discussed below. Results of all specialized metabolic testing should be reviewed by a specialist in IEM (usually the medical director of the laboratory) to assist with interpretation.",
"   </p>",
"   <p>",
"    Laboratory findings in IEM are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link&amp;anchor=H28#H28\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\", section on 'Laboratory findings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14591242\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of IEM is discussed in detail separately (",
"    <a class=\"graphic graphic_table graphicRef67745 \" href=\"UTD.htm?1/63/2045\">",
"     table 11",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76373 \" href=\"UTD.htm?37/63/38908\">",
"     table 12",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link&amp;anchor=H366024#H366024\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\", section on 'Initial evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12033857\">",
"    <span class=\"h2\">",
"     Specialized tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common specialized tests for IEM include quantitative plasma amino acids, qualitative urine organic acids, serum lactate, and acylcarnitine profile. These tests should only be performed as indicated by the clinical presentation and initial laboratory evaluation, although the samples should be obtained at the time of acute presentation, if possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12033906\">",
"    <span class=\"h3\">",
"     Plasma amino acids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quantitative amino acid analysis in plasma or serum is used to confirm the diagnosis of urea cycle disorders (",
"    <a class=\"graphic graphic_figure graphicRef60652 \" href=\"UTD.htm?2/49/2832\">",
"     figure 3",
"    </a>",
"    ) and other disorders of amino acid metabolism (",
"    <a class=\"graphic graphic_table graphicRef73440 \" href=\"UTD.htm?12/14/12526\">",
"     table 13",
"    </a>",
"    ). Quantitative plasma amino acid analysis is typically performed by high pressure liquid chromatography (HPLC), although tandem mass spectroscopy",
"    <span class=\"nowrap\">",
"     (MS/MS)",
"    </span>",
"    can also be used to measure amino acids. Amino acid analysis must be performed quantitatively rather than qualitatively. When a qualitative amino acid screen is performed by two-dimensional paper chromatography, elevations are reported only in groups of amino acids and specific disorders cannot be identified reliably.",
"   </p>",
"   <p>",
"    Most amino acids (except argininosuccinic acid and alloisoleucine) are present in the plasma within a normal range in healthy individuals. Mild elevations of 5 to 10 percent above normal usually are not significant. Fasting or a recent meal can affect plasma levels of some amino acids. The significance of elevated or reduced levels of specific amino acids is indicated in the table (",
"    <a class=\"graphic graphic_table graphicRef73440 \" href=\"UTD.htm?12/14/12526\">",
"     table 13",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12033913\">",
"    <span class=\"h3\">",
"     Urine organic acids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analysis of organic acids in urine is performed by gas",
"    <span class=\"nowrap\">",
"     chromatography/mass",
"    </span>",
"    spectrometry",
"    <span class=\"nowrap\">",
"     (GC/MS).",
"    </span>",
"    A qualitative assay of these compounds is adequate because pathogenic organic acids (eg, methylmalonic or propionic acid) are not present in significant amounts in the urine of normal individuals (",
"    <a class=\"graphic graphic_table graphicRef50227 \" href=\"UTD.htm?12/23/12669\">",
"     table 14",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12033920\">",
"    <span class=\"h3\">",
"     Lactate and pyruvate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lactate and pyruvate should be measured in arterial blood (tourniquet pressure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hemolysis may increase the lactate level erroneously [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13177/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]), and transported on ice [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13177/abstract/10\">",
"     10",
"    </a>",
"    ]. For accurate measurement of pyruvate, the sample must be collected in perchlorate (or a similar media) to inactivate enzymes that degrade pyruvate.",
"   </p>",
"   <p>",
"    Lactic acidosis caused by abnormal oxidative metabolism is a frequent finding in mitochondrial disorders (eg, disorders of oxidative phosphorylation), glycogen storage diseases (GSD), disorders of gluconeogenesis, and disorders of pyruvate metabolism. The ratio of lactate to pyruvate (normal value 10:1 to 20:1) may be helpful in differentiating among these conditions. The lactate-to-pyruvate ratio typically is high in mitochondrial disorders and in pyruvate carboxylase deficiency and normal or low in GSD and pyruvate dehydrogenase deficiency. However, exceptions occur, and the lactate-to-pyruvate ratio sometimes is normal in mitochondrial disorders. Elevated lactic acid also may be present in disorders of amino acid metabolism, organic acidemias, and fatty acid oxidation disorders (",
"    <a class=\"graphic graphic_table graphicRef76373 \" href=\"UTD.htm?37/63/38908\">",
"     table 12",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients with abnormal arterial lactate and pyruvate values may benefit from the following tests:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Triglycerides and uric acid to detect elevations seen in some GSD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=see_link\">",
"       \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Brain magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) to detect basal ganglia abnormalities associated with mitochondrial disorders and to measure the level of intracellular lactate and other metabolites.",
"     </li>",
"     <li>",
"      Muscle biopsy for routine staining, electron microscopy, and special stains for mitochondrial enzymes, with tissue frozen for pyruvate enzyme studies and electron transport chain studies to diagnose deficiencies of the mitochondrial respiratory chain.",
"     </li>",
"     <li>",
"      Echocardiogram to identify the cardiac dysfunction seen in some mitochondrial disorders.",
"     </li>",
"     <li>",
"      Muscle",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      skin biopsy to test enzymes involved in pyruvate metabolism (note that while these studies can be done on skin, they are more reliable when performed on muscle tissue due to higher levels of enzyme expression in muscle).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12033927\">",
"    <span class=\"h3\">",
"     Acylcarnitine profile",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analysis of acylcarnitine conjugates is performed by tandem mass spectrometry",
"    <span class=\"nowrap\">",
"     (MS/MS)",
"    </span>",
"    and can be measured in a plasma sample or a filter-paper bloodspot. This test is used for the diagnosis of fatty acid oxidation disorders; it also may detect organic acidemias in which the acylcarnitine profile is abnormal (eg, propionic acidemia, isovaleric acidemia). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=see_link\">",
"     \"Organic acidemias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=see_link\">",
"     \"Causes of metabolic myopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12033934\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other specialized tests in the evaluation of IEM may include [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13177/abstract/8,10,17,18\">",
"     8,10,17,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eye examination by an ophthalmologist to detect characteristic features of specific IEM (",
"      <a class=\"graphic graphic_table graphicRef64851 \" href=\"UTD.htm?29/17/29980\">",
"       table 15",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Echocardiogram to evaluate the presence of cardiomyopathy.",
"     </li>",
"     <li>",
"      Skin, skeletal muscle, or liver biopsy for enzyme assay, histology, or electron microscopy.",
"     </li>",
"     <li>",
"      Lumbar puncture for measurement of glucose, protein, lactate, pyruvate, glycine, serine, alanine, organic acids, neurotransmitters, pterins, or other disease specific metabolites.",
"     </li>",
"     <li>",
"      Serum ketones (beta-hydroxybutyrate, acetoacetate)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      free fatty acids in children with hypoglycemia.",
"     </li>",
"     <li>",
"      Quantitative plasma",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"       carnitine",
"      </a>",
"      levels (free, total, and acylcarnitine) if fatty acid oxidation disorders are suspected.",
"     </li>",
"     <li>",
"      Urine sulfocysteine for sulfite oxidase and molybdenum cofactor deficiencies.",
"     </li>",
"     <li>",
"      Urine",
"      <span class=\"nowrap\">",
"       purine/pyrimidine",
"      </span>",
"      panel analysis to assess for disorders of purine and pyrimidine metabolism.",
"     </li>",
"     <li>",
"      Urine polyol analysis to assess disorders of polyol metabolism.",
"     </li>",
"     <li>",
"      Plasma and urine creatine and guanidinoacetate levels to assess for abnormalities of creatine metabolism, such as guanidinoacetate methyltransferase deficiency. Plasma analysis alone cannot reliably detect X-linked creatine transporter deficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11015?source=see_link&amp;anchor=H21#H21\">",
"       \"Overview of peripheral nerve and muscle disorders causing hypotonia in the newborn\", section on 'Disorders of creatine metabolism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Urinary glycosaminoglycans and oligosaccharides to evaluate the possibility of lysosomal storage disorders.",
"     </li>",
"     <li>",
"      Carbohydrate deficient transferrin (abnormally glycosylated transferrin isoforms) for congenital disorders of glycosylation.",
"     </li>",
"     <li>",
"      Very long chain fatty acid analysis for peroxisomal disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=see_link\">",
"       \"Peroxisomal disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Uric acid (elevated in patients with GSD and Lesch-Nyhan disease and decreased in patients with defects of purine metabolism or molybdenum cofactor deficiency).",
"     </li>",
"     <li>",
"      Plasma and urine",
"      <span class=\"nowrap\">",
"       creatine/guanidinoacetate",
"      </span>",
"      test for creatine metabolism disorders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2368162\">",
"    <span class=\"h1\">",
"     EVALUATION OF SPECIFIC PRESENTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic approach to the child with suspected IEM depends to some extent upon the clinical presentation. In some cases, the clinical presentation suggests a particular disorder, and the diagnostic evaluation can be streamlined. In other cases, the clinical presentation may be associated with certain groups of metabolic disorders, and narrowing the differential diagnosis requires additional testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27047?source=see_link\">",
"     \"Inborn errors of metabolism: Classification\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link&amp;anchor=H669988#H669988\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\", section on 'Evaluation of specific critical presentations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnostic approaches for the most common chronic clinical presentations of IEM are presented below. These presentations are associated with certain groups of metabolic disorders, and narrowing the differential diagnosis requires additional testing. Diagnostic confirmation for specific disorders is discussed in the individual topic reviews related to the disorder (eg, (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27590?source=see_link\">",
"     \"Overview of maple syrup urine disease\"",
"    </a>",
"    )).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11382871\">",
"    <span class=\"h2\">",
"     Metabolic emergencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of critical presentations is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link&amp;anchor=H669988#H669988\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\", section on 'Evaluation of specific critical presentations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25935251\">",
"    <span class=\"h2\">",
"     Developmental delay",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation for IEM in children with developmental delay or regression should be individually tailored based upon the clinical history and physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13177/abstract/17\">",
"     17",
"    </a>",
"    ]. The possibility of an IEM in a child with developmental delay or intellectual disability of unknown etiology should be reviewed periodically, since signs and symptoms of some IEM may become more apparent over time (eg, hepatomegaly in lysosomal storage disorders). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link&amp;anchor=H11#H11\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\", section on 'Developmental delay'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/10/26793?source=see_link\">",
"     \"Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5257?source=see_link\">",
"     \"Intellectual disability (mental retardation) in children: Evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies to consider include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Quantitative plasma amino acid analysis (see",
"      <a class=\"local\" href=\"#H12033906\">",
"       'Plasma amino acids'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Qualitative urine organic acid analysis (see",
"      <a class=\"local\" href=\"#H12033913\">",
"       'Urine organic acids'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Serum lactate (preferably arterial) (see",
"      <a class=\"local\" href=\"#H12033920\">",
"       'Lactate and pyruvate'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Serum uric acid and creatine kinase to screen for GSD (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=see_link\">",
"       \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Quantitative urine mucopolysaccharides and oligosaccharides to detect lysosomal storage disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13177/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Plasma and urine creatine and guanidinoacetate levels to detect disorders of creatine metabolism, such as guanidinoacetate methyltransferase deficiency. Plasma analysis alone cannot reliably detect X-linked creatine transporter deficiency.",
"     </li>",
"     <li>",
"      Serum phytanic acid and very long-chain fatty acids to diagnose peroxisomal disorders.",
"     </li>",
"     <li>",
"      Dilated ophthalmologic exam to detect optic atrophy or retinal findings seen in peroxisomal, lysosomal storage, and mitochondrial disorders (",
"      <a class=\"graphic graphic_table graphicRef64851 \" href=\"UTD.htm?29/17/29980\">",
"       table 15",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Brain magnetic resonance imaging (MRI) to assess for leukodystrophy or basal ganglia changes found in lysosomal storage or mitochondrial disorders, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25935258\">",
"    <span class=\"h2\">",
"     Hepatosplenomegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Associated findings that suggest a particular IEM and help direct the diagnostic evaluation are discussed in detail separately. The etiology of acute liver failure is also reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link&amp;anchor=H19#H19\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\", section on 'Organomegaly'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22394?source=see_link\">",
"     \"Acute liver failure in children: Etiology and evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest the following studies if the hepatomegaly",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    splenomegaly are isolated or if no associated clinical or laboratory features are present:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plasma lactate, triglycerides, uric acid, and creatine kinase to screen for GSD (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=see_link\">",
"       \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Quantitative urine mucopolysaccharides and oligosaccharides to screen for lysosomal storage disorders",
"     </li>",
"     <li>",
"      Red blood cell galactose-1-phosphate (if patient has not received a blood transfusion)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      urine galactitol level to assess for galactosemia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30886?source=see_link\">",
"       \"Clinical features and diagnosis of galactosemia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Serum very long-chain fatty acids to detect peroxisomal disorders (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=see_link\">",
"       \"Peroxisomal disorders\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Quantitative plasma amino acid analysis and urine organic acid analysis for tyrosinemia type 1 (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23624?source=see_link\">",
"       \"Disorders of tyrosine metabolism\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Liver biopsy to evaluate the type and location of abnormal storage material with a frozen sample of unfixed liver saved for further diagnostic studies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the diagnosis is not established after the above evaluation, further testing may include enzyme assays on white blood cells (eg, Gaucher, Niemann-Pick, or sialidosis), urine bile acid analysis (disorders of bile acid metabolism), transferrin isoelectric focusing (congenital disorders of glycosylation), and acid lipase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25935265\">",
"    <span class=\"h2\">",
"     Cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiomyopathy due to IEM can be hypertropic or dilated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link&amp;anchor=H21#H21\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\", section on 'Cardiomyopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=see_link\">",
"     \"Causes of dilated cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22696?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of hypertrophic cardiomyopathy management including treatment of special problems\", section on 'Children with HCM'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypertrophic cardiomyopathy may occur in lysosomal acid maltase deficiency (GSD type II, Pompe disease) and mucopolysaccharidoses. The diagnosis of these conditions is established by alpha glucosidase (acid maltase) enzyme assay or quantitative urine mucopolysaccharide measurement, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17736?source=see_link\">",
"     \"Lysosomal acid maltase deficiency (glycogen storage disease II, Pompe disease)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7274?source=see_link\">",
"     \"Clinical features and diagnosis of the mucopolysaccharidoses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dilated cardiomyopathy can occur in fatty acid oxidation disorders, organic acidemias, and mitochondrial disorders (eg, disorders of oxidative phosphorylation). The initial evaluation includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plasma acylcarnitine profile (see",
"      <a class=\"local\" href=\"#H12033927\">",
"       'Acylcarnitine profile'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Quantitative plasma",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"       carnitine",
"      </a>",
"      levels (see",
"      <a class=\"local\" href=\"#H12033934\">",
"       'Other'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Qualitative urine organic acid analysis (see",
"      <a class=\"local\" href=\"#H12033913\">",
"       'Urine organic acids'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Serum lactate and pyruvate levels (see",
"      <a class=\"local\" href=\"#H12033920\">",
"       'Lactate and pyruvate'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Skeletal muscle biopsy for routine examination, electron microscopy, and mitochondrial enzyme stains. A frozen tissue sample should be kept for electron transport chain studies to be used in the diagnosis of mitochondrial disorders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25935272\">",
"    <span class=\"h2\">",
"     Skeletal myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myopathy (muscle weakness, tenderness, cramping, atrophy, or exercise intolerance) can occur in lysosomal and nonlysosomal glycogen storage diseases (GSD), disorders of fatty acid oxidation, and mitochondrial disorders (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link&amp;anchor=H14#H14\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\", section on 'Myopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/56/905?source=see_link\">",
"     \"Approach to the metabolic myopathies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=see_link\">",
"     \"Causes of metabolic myopathies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26694?source=see_link\">",
"     \"Approach to the patient with muscle weakness\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Additional evaluation of patients with myopathy includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Creatine kinase, aldolase, triglycerides, uric acid, and to detect GSD (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=see_link\">",
"       \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36745?source=see_link&amp;anchor=H15#H15\">",
"       \"Muscle enzymes in the evaluation of neuromuscular diseases\", section on 'Metabolic myopathies'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Plasma acylcarnitine profile (see",
"      <a class=\"local\" href=\"#H12033927\">",
"       'Acylcarnitine profile'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Quantitative plasma",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"       carnitine",
"      </a>",
"      levels (see",
"      <a class=\"local\" href=\"#H12033934\">",
"       'Other'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Serum lactate (preferably arterial) (see",
"      <a class=\"local\" href=\"#H12033920\">",
"       'Lactate and pyruvate'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Skeletal muscle biopsy for routine examination, electron microscopy, and mitochondrial enzyme stains. A frozen tissue sample should be kept for electron transport chain studies to be used in the diagnosis of mitochondrial disorders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The approach to the metabolic myopathies is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/56/905?source=see_link\">",
"     \"Approach to the metabolic myopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25935279\">",
"    <span class=\"h2\">",
"     Post-mortem",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-mortem evaluation of children with suspected, but undiagnosed, IEM at the time of death is essential to determine the cause of death and to permit accurate counseling regarding the cause of death, the recurrence risk for the family, and prenatal diagnosis of future pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13177/abstract/8,10,18\">",
"     8,10,18",
"    </a>",
"    ]. In one review of all metabolic autopsies performed at a tertiary care children's hospital over a five-year period, metabolic autopsy successfully identified an undiagnosed metabolic disease in 18 percent of 23 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13177/abstract/19\">",
"     19",
"    </a>",
"    ]. Such identification was less likely in patients who had undergone extensive premorbid clinical evaluation without diagnosis.",
"   </p>",
"   <p>",
"    Autopsy is typically performed in cases of unexpected death. However, routine autopsy may not provide information related to IEM [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13177/abstract/10,18\">",
"     10,18",
"    </a>",
"    ]. If adequate information is to be obtained, it is essential to collect relevant blood, urine, and tissue specimens before or shortly after death (ie, within one to two hours if possible) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13177/abstract/4,8,18\">",
"     4,8,18",
"    </a>",
"    ]. Plasma amino acids, lactate, pyruvate, and total and free",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"     carnitine",
"    </a>",
"    are not accurate when post-mortem specimens are analyzed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13177/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the parents grant permission, appropriate samples should be obtained in consultation with a specialist in genetic or metabolic disease, and may include [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13177/abstract/4,8,10,18\">",
"     4,8,10,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several blood spots (four to six) on a newborn screening card or filter paper for acylcarnitine analysis or other studies.",
"     </li>",
"     <li>",
"      Plasma (3 to 5 mL) in",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/38/1639?source=see_link\">",
"       lithium",
"      </a>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       heparin",
"      </a>",
"      tube, separated and frozen at -70&ordm;C.",
"     </li>",
"     <li>",
"      Whole blood (5 to 10 mL) in EDTA tube for DNA analysis; the sample should be refrigerated, not frozen; other whole blood samples may be used if necessary.",
"     </li>",
"     <li>",
"      Urine (5 to 10 mL, or more if possible, in 1 to 2 mL aliquots) frozen in plain sterile containers.",
"     </li>",
"     <li>",
"      CSF (3 to 5 mL, in one mL aliquots) frozen and stored at -70&ordm;C.",
"     </li>",
"     <li>",
"      Vitreous humor for organic acid analysis if urine is not available (collected by intraocular puncture at autopsy, frozen at -20&ordm;C or -70&ordm;C) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13177/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Skin biopsy for fibroblast culture. Specimens, 3 mm in diameter, should be obtained by punch or incisional biopsy from the flexor surface of the forearm and anterior thigh using sterile technique. The specimens should be refrigerated (not frozen) in tissue culture medium, if available, or viral culture medium or normal saline if tissue culture medium is not available.",
"     </li>",
"     <li>",
"      Two fresh (unfixed) samples of muscle (1 cm",
"      <sup>",
"       3",
"      </sup>",
"      ); one sample frozen in liquid nitrogen or dry ice for enzyme analysis, histology, and DNA analysis; the other sample stored in appropriate medium (eg, glutaraldehyde) for electron microscopy.",
"     </li>",
"     <li>",
"      Two fresh (unfixed) samples of liver (1 cm",
"      <sup>",
"       3",
"      </sup>",
"      ); one sample frozen in liquid nitrogen or dry ice for enzyme analysis, histology, and DNA analysis; the other sample stored in appropriate medium (eg, glutaraldehyde) for electron microscopy. If autopsy is not performed, it may be possible to obtain permission for postmortem needle biopsy of the liver for histologic studies (if indicated).",
"     </li>",
"     <li>",
"      If specimens are otherwise unavailable, it may be possible to retrieve archived newborn screening blood spots on filter paper for analysis by tandem mass spectrometry",
"      <span class=\"nowrap\">",
"       (MS/MS)",
"      </span>",
"      or other methodology.",
"     </li>",
"     <li>",
"      Additional post-mortem evaluation may include photographs of dysmorphic features,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiographic studies to evaluate neurologic, cardiac, or skeletal abnormalities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5820258\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Optimal outcome for children with inborn errors of metabolism (IEM) (",
"      <a class=\"graphic graphic_table graphicRef82924 \" href=\"UTD.htm?39/44/40651\">",
"       table 1",
"      </a>",
"      ) depends upon early recognition. Delay in diagnosis may result in acute metabolic decompensation, progressive neurologic injury, or death. (See",
"      <a class=\"local\" href=\"#H5818513\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although newborn screening programs increase the detection of IEM, they cannot be relied upon exclusively. Improved detection depends upon a high index of suspicion. (See",
"      <a class=\"local\" href=\"#H2926302\">",
"       'Newborn screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The history in a patient with IEM should focus on previous episodes of metabolic decompensation, identification of potential triggering events, and family history of metabolic disease or members with similar presentations. (See",
"      <a class=\"local\" href=\"#H12033756\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The examination is often normal, but may provide clues to specific disorders (",
"      <a class=\"graphic graphic_table graphicRef51536 \" href=\"UTD.htm?11/26/11694\">",
"       table 10",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12033797\">",
"       'Examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory evaluation for IEM should be undertaken in all patients with suggestive history, examination,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      abnormalities of routine laboratory tests. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link\">",
"       \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link&amp;anchor=H16728975#H16728975\">",
"       \"Inborn errors of metabolism: Metabolic emergencies\", section on 'Clinical presentations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link&amp;anchor=H3681940#H3681940\">",
"       \"Inborn errors of metabolism: Metabolic emergencies\", section on 'Laboratory findings'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H12033749\">",
"       'Clinical evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12033830\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Testing should be performed at the time of presentation or when symptoms are most pronounced. Patients with life-threatening illness should undergo concurrent evaluation for other conditions in the differential diagnosis. (See",
"      <a class=\"local\" href=\"#H12033830\">",
"       'Laboratory evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link&amp;anchor=H363620#H363620\">",
"       \"Inborn errors of metabolism: Metabolic emergencies\", section on 'Differential diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest a stepwise approach to the laboratory evaluation, beginning with basic tests that are routinely available, before obtaining specialized metabolic investigations (",
"      <a class=\"graphic graphic_table graphicRef67745 \" href=\"UTD.htm?1/63/2045\">",
"       table 11",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef76373 \" href=\"UTD.htm?37/63/38908\">",
"       table 12",
"      </a>",
"      ). Decisions regarding specialized testing are best undertaken in consultation with a specialist in genetics or metabolic disorders and laboratory personnel to make sure that specimens are obtained, processed, and analyzed appropriately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link&amp;anchor=H366024#H366024\">",
"       \"Inborn errors of metabolism: Metabolic emergencies\", section on 'Initial evaluation'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H12033857\">",
"       'Specialized tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnostic approach to the child with suspected IEM depends upon the clinical presentation. When the clinical presentation suggests a particular disorder, the evaluation can be streamlined; when the clinical presentation is associated with certain groups of disorders, additional testing is needed to narrow the differential diagnosis. Additional evaluation for developmental delay or regression, hepatomegaly, cardiomyopathy, and skeletal myopathy are discussed above. Critical presentations are discussed separately. (See",
"      <a class=\"local\" href=\"#H2368162\">",
"       'Evaluation of specific presentations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link&amp;anchor=H669988#H669988\">",
"       \"Inborn errors of metabolism: Metabolic emergencies\", section on 'Evaluation of specific critical presentations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Post-mortem evaluation of children with suspected, but undiagnosed, IEM at the time of death is essential to determine the cause of death and to permit subsequent genetic counseling",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      prenatal diagnosis. (See",
"      <a class=\"local\" href=\"#H25935279\">",
"       'Post-mortem'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13177/abstract/1\">",
"      Champion MP. An approach to the diagnosis of inherited metabolic disease. Arch Dis Child Educ Pract Ed 2010; 95:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13177/abstract/2\">",
"      Pasquali M, Longo N. Newborn screening and inborn errors of metabolism. Am J Med Genet C Semin Med Genet 2011; 157:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13177/abstract/3\">",
"      Couce ML, Casti&ntilde;eiras DE, B&oacute;veda MD, et al. Evaluation and long-term follow-up of infants with inborn errors of metabolism identified in an expanded screening programme. Mol Genet Metab 2011; 104:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13177/abstract/4\">",
"      Leonard JV, Morris AA. Diagnosis and early management of inborn errors of metabolism presenting around the time of birth. Acta Paediatr 2006; 95:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13177/abstract/5\">",
"      Wilcken B, Leung KC, Hammond J, et al. Pregnancy and fetal long-chain 3-hydroxyacyl coenzyme A dehydrogenase deficiency. Lancet 1993; 341:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13177/abstract/6\">",
"      Mansouri A, Fromenty B, Durand F, et al. Assessment of the prevalence of genetic metabolic defects in acute fatty liver of pregnancy. J Hepatol 1996; 25:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13177/abstract/7\">",
"      Walter JH. Inborn errors of metabolism and pregnancy. J Inherit Metab Dis 2000; 23:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13177/abstract/8\">",
"      Burton BK. Inborn errors of metabolism in infancy: a guide to diagnosis. Pediatrics 1998; 102:E69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13177/abstract/9\">",
"      Lindor NM, Karnes PS. Initial assessment of infants and children with suspected inborn errors of metabolism. Mayo Clin Proc 1995; 70:987.",
"     </a>",
"    </li>",
"    <li>",
"     Weiner DL. Metabolic emergencies. In: Textbook of pediatric emergency medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott, Williams and Wilkins, Philadelphia 2006. p.1193.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13177/abstract/11\">",
"      Roth KS. Inborn errors of metabolism: the essentials of clinical diagnosis. Clin Pediatr (Phila) 1991; 30:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13177/abstract/12\">",
"      Ramaswami U, Whybra C, Parini R, et al. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 2006; 95:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13177/abstract/13\">",
"      Banikazemi M, Ullman T, Desnick RJ. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. Mol Genet Metab 2005; 85:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13177/abstract/14\">",
"      Calvo M, Artuch R, Maci&agrave; E, et al. Diagnostic approach to inborn errors of metabolism in an emergency unit. Pediatr Emerg Care 2000; 16:405.",
"     </a>",
"    </li>",
"    <li>",
"     Wappner RS, Hainline BE. Introduction to inborn errors of metabolism. In: Oski's pediatrics. Principles and practice, 4th ed, McMillan JA, Feigin RD, DeAngelis C, Jones MD (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. p.2145.",
"    </li>",
"    <li>",
"     Saudubray JM, Chappentier C. Clinical phenotypes: Diagnosis/algorithms. In: Metabolic and molecular bases of inherited disease, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001. p.1327.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13177/abstract/17\">",
"      Cleary MA, Green A. Developmental delay: when to suspect and how to investigate for an inborn error of metabolism. Arch Dis Child 2005; 90:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13177/abstract/18\">",
"      Chakrapani A, Cleary MA, Wraith JE. Detection of inborn errors of metabolism in the newborn. Arch Dis Child Fetal Neonatal Ed 2001; 84:F205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13177/abstract/19\">",
"      Ernst LM, Sondheimer N, Deardorff MA, et al. The value of the metabolic autopsy in the pediatric hospital setting. J Pediatr 2006; 148:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13177/abstract/20\">",
"      Bennett MJ, Ragni MC, Hood I, Hale DE. Comparison of post-mortem urinary and vitreous humour organic acids. Ann Clin Biochem 1992; 29 ( Pt 5):541.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17216 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-189.41.172.26-C8F2277E62-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_55_13177=[""].join("\n");
var outline_f12_55_13177=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5820258\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5818513\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2926302\">",
"      NEWBORN SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12033749\">",
"      CLINICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12033756\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12033797\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12033830\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14591242\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12033857\">",
"      Specialized tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12033906\">",
"      - Plasma amino acids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12033913\">",
"      - Urine organic acids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12033920\">",
"      - Lactate and pyruvate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12033927\">",
"      - Acylcarnitine profile",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12033934\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2368162\">",
"      EVALUATION OF SPECIFIC PRESENTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11382871\">",
"      Metabolic emergencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25935251\">",
"      Developmental delay",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25935258\">",
"      Hepatosplenomegaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25935265\">",
"      Cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25935272\">",
"      Skeletal myopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25935279\">",
"      Post-mortem",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5820258\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/17216\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/17216|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/7/2174\" title=\"figure 1\">",
"      X-linked recessive pedigree",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/53/2910\" title=\"figure 2\">",
"      Mitochondrial pedigree",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/49/2832\" title=\"figure 3\">",
"      Urea cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/17216|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/44/40651\" title=\"table 1\">",
"      Types of inborn errors of metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/23/8572\" title=\"table 2\">",
"      Disorders of carbohydrate metab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/13/8411\" title=\"table 3\">",
"      Mitochondrial disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/62/22507\" title=\"table 4\">",
"      Peroxisomal disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/60/8140\" title=\"table 5\">",
"      Selected lysosomal storage disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/12/24780\" title=\"table 6\">",
"      Disorders of fatty acid oxidation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/50/25387\" title=\"table 7\">",
"      Metabolic causes hydrops",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/6/43116\" title=\"table 8\">",
"      Acute porphyrias drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/22/19821\" title=\"table 9\">",
"      Drugs and G6PD deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/26/11694\" title=\"table 10\">",
"      Examination clues IEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/63/2045\" title=\"table 11\">",
"      Laboratory evaluation for inborn errors of metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/63/38908\" title=\"table 12\">",
"      Laboratory findings inborn errors of metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/14/12526\" title=\"table 13\">",
"      Amino acid levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/23/12669\" title=\"table 14\">",
"      Abnormal urine organic acids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/17/29980\" title=\"table 15\">",
"      Ophth findings IEM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22394?source=related_link\">",
"      Acute liver failure in children: Etiology and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/56/905?source=related_link\">",
"      Approach to the metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26694?source=related_link\">",
"      Approach to the patient with muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=related_link\">",
"      Causes of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=related_link\">",
"      Causes of metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40137?source=related_link\">",
"      Clinical features and diagnosis of Fabry disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30886?source=related_link\">",
"      Clinical features and diagnosis of galactosemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7274?source=related_link\">",
"      Clinical features and diagnosis of the mucopolysaccharidoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10439?source=related_link\">",
"      Clinical manifestations and diagnosis of acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12584?source=related_link\">",
"      Cystinosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23624?source=related_link\">",
"      Disorders of tyrosine metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16010?source=related_link\">",
"      Etiology of hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27047?source=related_link\">",
"      Inborn errors of metabolism: Classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=related_link\">",
"      Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=related_link\">",
"      Inborn errors of metabolism: Metabolic emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/10/26793?source=related_link\">",
"      Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5257?source=related_link\">",
"      Intellectual disability (mental retardation) in children: Evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17736?source=related_link\">",
"      Lysosomal acid maltase deficiency (glycogen storage disease II, Pompe disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36745?source=related_link\">",
"      Muscle enzymes in the evaluation of neuromuscular diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2088?source=related_link\">",
"      Newborn screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=related_link\">",
"      Nonimmune hydrops fetalis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=related_link\">",
"      Organic acidemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22696?source=related_link\">",
"      Overview of hypertrophic cardiomyopathy management including treatment of special problems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=related_link\">",
"      Overview of inherited disorders of glucose and glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27590?source=related_link\">",
"      Overview of maple syrup urine disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11015?source=related_link\">",
"      Overview of peripheral nerve and muscle disorders causing hypotonia in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3866?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of persistent hyperinsulinemic hypoglycemia of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=related_link\">",
"      Peroxisomal disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20248?source=related_link\">",
"      Urea cycle disorders: Clinical features and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_55_13178="Overview of IgG4-related disease";
var content_f12_55_13178=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of IgG4-related disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/55/13178/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/55/13178/contributors\">",
"     Haralampos M Moutsopoulos, MD, FACP, FRCP, Master ACR",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/55/13178/contributors\">",
"     George E Fragoulis, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/55/13178/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/55/13178/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/55/13178/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/55/13178/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/55/13178/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/55/13178/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H16601895\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoglobulin G4-related disease (IgG4-RD) is an increasingly recognized syndrome of unknown etiology comprised of a collection of disorders that share specific pathologic, serologic, and clinical features [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/1\">",
"     1",
"    </a>",
"    ]. These different conditions were previously thought to be unrelated [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The commonly shared features include tumor-like swelling of involved organs, a lymphoplasmacytic infiltrate enriched in IgG4-positive plasma cells, and variable degrees of fibrosis that has a characteristic &ldquo;storiform&rdquo; pattern (",
"    <a class=\"graphic graphic_picture graphicRef76767 \" href=\"UTD.htm?13/25/13721\">",
"     picture 1",
"    </a>",
"    ). In addition, elevated serum concentrations of IgG4 are found in 60 to 70 percent of patients with IgG4-RD.",
"   </p>",
"   <p>",
"    The majority of patients respond to glucocorticoids, particularly in early stages of disease. In some subsets of organ disease (eg, pancreatitis), glucocorticoid responsiveness has been considered one diagnostic criterion for the disorder.",
"   </p>",
"   <p>",
"    Two major presentations of this condition, which often affects more than one organ, are type 1 autoimmune pancreatitis (IgG4-related pancreatitis) and salivary gland disease; the latter may present as salivary gland enlargement or as sclerosing sialadenitis (formerly termed &ldquo;Mikulicz disease&rdquo; and K&uuml;ttner&rsquo;s tumor, respectively). These conditions often resemble Sj&ouml;gren&rsquo;s syndrome but are pathophysiologically distinct from this disorder. The preferred name for the overall condition is IgG4-related disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. However, multiple names have been employed to describe this entity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      IgG4-related disease",
"     </li>",
"     <li>",
"      IgG4-related systemic disease",
"     </li>",
"     <li>",
"      IgG4-syndrome",
"     </li>",
"     <li>",
"      IgG4-associated disease",
"     </li>",
"     <li>",
"      IgG4-related sclerosing disease",
"     </li>",
"     <li>",
"      IgG4-related systemic sclerosing disease",
"     </li>",
"     <li>",
"      IgG4-related autoimmune disease",
"     </li>",
"     <li>",
"      IgG4-positive multiorgan lymphoproliferative syndrome",
"     </li>",
"     <li>",
"      Hyper-IgG4 disease",
"     </li>",
"     <li>",
"      Systemic IgG4-related plasmacytic syndrome",
"     </li>",
"     <li>",
"      Systemic IgG4-related sclerosing syndrome",
"     </li>",
"     <li>",
"      Multifocal fibrosclerosis",
"     </li>",
"     <li>",
"      Multifocal idiopathic fibrosclerosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will provide an overview of the clinical manifestations, diagnosis, and treatment of IgG4-related disease and several of its component entities. Type 1 autoimmune pancreatitis (IgG4-related pancreatitis) and IgG4-related sclerosing cholangitis are discussed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40168?source=see_link\">",
"     \"Autoimmune pancreatitis\"",
"    </a>",
"    ), as are several of the other conditions associated with this disorder (see appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4739538\">",
"    <span class=\"h1\">",
"     DEFINITION AND HISTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hallmarks of IgG4-related disease (IgG4-RD) are lymphoplasmacytic tissue infiltration with a predominance of IgG4-positive plasma cells and T lymphocytes, usually accompanied by fibrosis, obliterative phlebitis, and elevated serum levels of IgG4 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/7\">",
"     7",
"    </a>",
"    ]. A sizeable minority of patients (less than 40 percent) have normal serum IgG4 concentrations despite the presence of the classic histopathological changes in tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/8\">",
"     8",
"    </a>",
"    ]. A good initial therapeutic response to glucocorticoids is characteristic, particularly if excessive tissue fibrosis has not supervened [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The fibrosis associated with IgG4-RD has a characteristic &ldquo;storiform&rdquo; pattern, typified by a cartwheel appearance of the arranged fibroblasts and inflammatory cells, termed the &ldquo;nuclear streaming artifact&rdquo; (",
"    <a class=\"graphic graphic_picture graphicRef76767 \" href=\"UTD.htm?13/25/13721\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/7,10\">",
"     7,10",
"    </a>",
"    ]. Modest tissue eosinophilia is also common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11899448\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall disease epidemiology remains largely undefined. IgG4-RD is most often described as occurring in middle-aged and older men, but the sex distribution depends upon the index manifestation leading to study. Patients with type 1 autoimmune pancreatitis (IgG4-related pancreatitis), the best-studied group, are more often older men, although studies of IgG4-related sialadenitis have shown more equal sex distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/3,11,12\">",
"     3,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 114 patients with IgG4-RD, those with involvement limited to one of several regions (head and neck, thoracic, hepatopancreatobiliary, and retroperitoneal) and those with systemic involvement (more than one region) were compared with respect to various demographic and clinical features; the ages of patients in all groups were similar, with means from 59 to 68 years (ranges 42 to 79) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/12\">",
"     12",
"    </a>",
"    ]. All the groups, other than the patients with head and neck involvement, were predominantly men (75 to 86 percent), but the group with only head and neck disease was nearly equally divided (48 percent men). Definitive assessments of the incidence and prevalence of IgG4-RD in the general population or among different geographic or ethnic populations are lacking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365938\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of IgG4-related disease (IgG4-RD) is poorly understood; findings consistent with both an autoimmune disorder and an allergic disorder are present [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/7,13-19\">",
"     7,13-19",
"    </a>",
"    ]. IgG4 has been postulated to have a role in tolerance to allergens and in responses to certain infectious agents, but its physiologic role is poorly understood. A specific autoantigenic target has not been identified, and it is not clear whether the IgG4 antibodies are pathogenic [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/20\">",
"     20",
"    </a>",
"    ]. Elevations in serum and tissue IgG4 concentrations are not specific to IgG4-RD; they are also found in disorders such as multicentric Castleman&rsquo;s disease, allergic disorders, the Churg-Strauss syndrome, sarcoidosis, and a large number of other conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13258?source=see_link&amp;anchor=H9#H9\">",
"     \"IgG subclass deficiency\", section on 'IgG4 deficiency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35078?source=see_link&amp;anchor=H2#H2\">",
"     \"IgG subclasses: Physical properties, genetics, and biologic functions\", section on 'Properties of IgG subclasses'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=see_link&amp;anchor=H17#H17\">",
"     \"Diagnostic evaluation of food allergy\", section on 'Unvalidated methods'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35078?source=see_link&amp;anchor=H3397374#H3397374\">",
"     \"IgG subclasses: Physical properties, genetics, and biologic functions\", section on 'Disorders associated with elevated subclass levels'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Findings in IgG4-RD suggesting autoimmunity have been particularly evident in patients with type 1 autoimmune pancreatitis (IgG4-related pancreatitis), the prototypic IgG4-related disorder, including an association with a specific class II histocompatibility antigen genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/13\">",
"     13",
"    </a>",
"    ]. Antinuclear antibodies are sometimes present, and autoantibodies have been described against lactoferrin and carbonic anhydrase II. Some studies have suggested a possible role for molecular mimicry involving Helicobacter pylori [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/23\">",
"     23",
"    </a>",
"    ]. Immune complex deposition in the pancreas, kidneys, and certain other affected tissues has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/14\">",
"     14",
"    </a>",
"    ]. However, autoantibody studies have been inconsistent, and there is no definitive evidence for a role of autoimmunity in this disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40168?source=see_link\">",
"     \"Autoimmune pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence for an allergic response includes elevated levels of Th2 cytokines in affected tissues and increased amounts of serum IgE [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition, patients with IgG4-RD have an increased prevalence of allergic rhinitis and bronchial asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/11\">",
"     11",
"    </a>",
"    ]. There are increased numbers of T regulatory cells (Tregs) in peripheral blood and increased levels of cytokines produced by Tregs, including interleukin (IL)-10 and transforming growth factor (TGF)-&beta; in affected tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The Th2 cytokines, Tregs, and IL-10 help support IgG4 production [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/17,24\">",
"     17,24",
"    </a>",
"    ]. Up to 40 percent of patients with IgG4-RD have a peripheral eosinophilia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16601923\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgG4-related disease (IgG4-RD) is a disorder that can involve one or multiple organs. Patients often present with subacute development of a mass in the affected organ (eg, an orbital pseudotumor, a renal mass resembling renal cell carcinoma, or nodular lesions in the lung) or diffuse enlargement of an organ (eg, the pancreas) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/1,3,25\">",
"     1,3,25",
"    </a>",
"    ]. Multiple organs are affected in 60 to 90 percent of patients with IgG4-RD [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/4,26\">",
"     4,26",
"    </a>",
"    ]. The affected tissues share specific pathologic, serologic, and clinical features, regardless of the organ involved, in a manner analogous to the systemic involvement of sarcoidosis, another disorder with shared histopathologic features in the different tissues that are affected. Lymphadenopathy is common, and symptoms of asthma or allergy are present in approximately 40 percent of patients. Patients often feel well at the time of diagnosis and lack fever or other constitutional symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/7\">",
"     7",
"    </a>",
"    ]. IgG4-RD is also often recognized incidentally based upon a radiologic finding or histopathologic examination of a tissue specimen.",
"   </p>",
"   <p>",
"    The disorder has been viewed as uncommon, but components of this syndrome are now increasingly recognized in nearly every organ system. Many of the initial observations regarding this condition were made in patients with autoimmune pancreatitis, which often presents as a pancreatic mass or as painless obstructive jaundice, and can be mistaken for pancreatic cancer. Additional reports have focused on patients with lacrimal and salivary gland involvement, formerly termed Mikulicz&rsquo;s disease, which was once thought to be a subset of Sj&ouml;gren&rsquo;s syndrome (",
"    <a class=\"graphic graphic_picture graphicRef56827 \" href=\"UTD.htm?0/42/672\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/3,25\">",
"     3,25",
"    </a>",
"    ]. Such patients may present, for example, with prominent parotid or submandibular gland enlargement. The terms IgG4-related dacryoadenitis and IgG4-related sialadenitis are now used in place of Mikulicz&rsquo;s disease. IgG4-related dacryoadenitis and sialadenitis do not invariably occur together.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H250672027\">",
"    <span class=\"h2\">",
"     IgG4-RD associated disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previously described conditions that represent manifestations of IgG4-RD and the nomenclature, when not otherwise indicated, include [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type 1 autoimmune pancreatitis (IgG4-related pancreatitis)",
"     </li>",
"     <li>",
"      IgG4-related sclerosing cholangitis",
"     </li>",
"     <li>",
"      Mikulicz&rsquo;s disease (IgG4-related dacryoadenitis and sialadenitis)",
"     </li>",
"     <li>",
"      Sclerosing sialadenitis (K&uuml;ttner&rsquo;s tumor, IgG4-related submandibular gland disease)",
"     </li>",
"     <li>",
"      Inflammatory orbital pseudotumor (IgG4-related orbital inflammation or orbital inflammatory pseudotumor)",
"     </li>",
"     <li>",
"      Chronic sclerosing dacryoadenitis (lacrimal gland enlargement, IgG4-related dacryoadenitis)",
"     </li>",
"     <li>",
"      A subset of patients with &ldquo;idiopathic&rdquo; retroperitoneal fibrosis (Ormond&rsquo;s disease) and related disorders (IgG4-related retroperitoneal fibrosis, IgG4-related mesenteritis)",
"     </li>",
"     <li>",
"      Chronic sclerosing aortitis and periaortitis (IgG4-related aortitis or periaortitis)",
"     </li>",
"     <li>",
"      Riedel&rsquo;s thyroiditis (IgG4-related thyroid disease)",
"     </li>",
"     <li>",
"      IgG4-related interstitial pneumonitis and pulmonary inflammatory pseudotumors (IgG4-related lung disease)",
"     </li>",
"     <li>",
"      IgG4-related kidney disease (including tubulointerstitial nephritis and membranous glomerulonephritis secondary to IgG4-RD)",
"     </li>",
"     <li>",
"      IgG4-related hypophysitis",
"     </li>",
"     <li>",
"      IgG4-related pachymeningitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Estimates of the relative frequency of different manifestations depend upon the particular perspective of the index illness being studied. As an example, a study of patients with autoimmune pancreatitis found frequent extrapancreatic involvement, including hilar lymphadenopathy (80 percent), extrapancreatic bile duct lesions (74 percent), lacrimal and salivary gland lesions (39 percent), hypothyroidism (22 percent), and retroperitoneal fibrosis (13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/27\">",
"     27",
"    </a>",
"    ]. In contrast, autoimmune pancreatitis was found in only 17 percent of patients studied with IgG4-related lacrimal, parotid, or submandibular gland disease, and interstitial nephritis (17 percent) and interstitial pneumonitis (9 percent) were also seen among this group [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H250672034\">",
"    <span class=\"h3\">",
"     Lymphadenopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic IgG4-related lymphadenopathy is common, occurring in 80 percent of patients with autoimmune pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/27\">",
"     27",
"    </a>",
"    ]; it is usually observed together with other clinical or laboratory manifestations of the syndrome but may be the initial or only manifestation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/28\">",
"     28",
"    </a>",
"    ]. In a study of 114 patients with varied organ involvement, lymphadenopathy was present in 41 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/12\">",
"     12",
"    </a>",
"    ]. Symptoms occasionally occur due to mass effect of the enlarging nodes; individual nodes are typically no more than 2 centimeters in diameter but may range up to 5 centimeters [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/28\">",
"     28",
"    </a>",
"    ]. Multiple groups of lymph nodes are usually involved; the mediastinal, hilar, intra-abdominal, and axillary are most common and can be readily seen upon scanning with gallium-67 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Five histologic patterns may be seen, which all feature abundant IgG4 positive cells; the majority have eosinophil infiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/7,30,31\">",
"     7,30,31",
"    </a>",
"    ]. Histology is similar to other affected tissues, except that there is usually no sclerosis or phlebitis. The patterns include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type I &mdash; Multicentric Castleman disease-like",
"     </li>",
"     <li>",
"      Type II &mdash; Follicular hyperplasia",
"     </li>",
"     <li>",
"      Type III &mdash; Interfollicular expansion",
"     </li>",
"     <li>",
"      Type IV &mdash; Progressive transformation of germinal center-like",
"     </li>",
"     <li>",
"      Type V &mdash; Nodal inflammatory pseudotumor-like",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with lymphadenopathy may exhibit elevated serum IgG4, serum IgG and IgE, polyclonal hypergammaglobulinemia, and elevations in the erythrocyte sedimentation rate.",
"   </p>",
"   <p>",
"    The differential diagnosis in patients with generalized lymphadenopathy includes lymphoma, multicentric Castleman disease, or malignancy. IgG4-related lymphadenopathy is distinguished from these conditions by the modest lymph node enlargement, histologic distinctions on biopsy, lack of constitutional features, and the usually striking clinical response to glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/7\">",
"     7",
"    </a>",
"    ]. Patients with bilateral hilar adenopathy may mimic sarcoidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39080?source=see_link\">",
"     \"Evaluation of peripheral lymphadenopathy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=see_link\">",
"     \"Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6970?source=see_link&amp;anchor=H10#H10\">",
"     \"Castleman's disease\", section on 'Multicentric Castleman's disease'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H360096128\">",
"     'Lung and pleural disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16601930\">",
"    <span class=\"h2\">",
"     Autoimmune pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 1 autoimmune pancreatitis (IgG4-related pancreatitis) is the prototypical form of IgG4-RD. The prevalence of this condition in Japan has been estimated to be 0.82 per 100,000 persons, but this is likely to be an underestimate as clinical recognition of this disorder is growing [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Two types of autoimmune pancreatitis (AIP) have been distinguished; the form associated with IgG4-RD is type 1 AIP, also denoted as lymphoplasmacytic sclerosing pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/26\">",
"     26",
"    </a>",
"    ]. AIP is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40168?source=see_link\">",
"     \"Autoimmune pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AIP has been estimated to account for 2 percent of patients with chronic pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/32\">",
"     32",
"    </a>",
"    ]. It often presents as a pancreatic mass or as painless obstructive jaundice and can be mistaken for pancreatic cancer. Some patients with type 1 AIP exhibit acute, recurrent, or chronic pancreatitis, and AIP is frequently associated with diabetes mellitus. Most patients have another IgG4-related condition, such as IgG4-related sclerosing cholangitis, lymphadenopathy, or salivary or lacrimal gland involvement. (See",
"    <a class=\"local\" href=\"#H16601923\">",
"     'Clinical manifestations'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40168?source=see_link\">",
"     \"Autoimmune pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differentiation of AIP from adenocarcinoma of the pancreas is sometimes difficult on the basis of clinical presentations. Painless jaundice, for example, is common to both. Many patients have undergone Whipple procedures with the intention of treating pancreatic cancer. IgG4-positive plasma cells can also be found in the diseased pancreatic tissue in these conditions, although to a lesser degree than in AIP. Elevated serum IgG4 levels (&gt;135",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    can also be seen in some patients with pancreatic cancer, although they are usually less than twice the upper limit of normal; thus, increased IgG4 serum levels alone cannot be used to exclude a diagnosis of pancreatic malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/34\">",
"     34",
"    </a>",
"    ]. Radiologic features of type I AIP include diffuse enlargement of the pancreas, leading to the descriptor &ldquo;sausage-shaped&rdquo; pancreas, and a halo of edema surrounding the organ. Both of these features are appreciated most readily on abdominal computerized tomographic (CT) scanning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16601937\">",
"    <span class=\"h2\">",
"     IgG4-related sclerosing cholangitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A form of sclerosing cholangitis that is clinically distinct from primary sclerosing cholangitis may occur as part of the IgG4-RD. IgG4-related cholangitis is the most frequent extrapancreatic manifestation of type 1 AIP (IgG4-related), present in over 70 percent of such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/3\">",
"     3",
"    </a>",
"    ]. It also rarely occurs in the absence of pancreatitis. The clinical distinction between primary sclerosing cholangitis and IgG4-related sclerosing cholangitis can be difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/17,35\">",
"     17,35",
"    </a>",
"    ], but attempts to do so are critical because of the drastically different prognoses in these conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40168?source=see_link&amp;anchor=H5#H5\">",
"     \"Autoimmune pancreatitis\", section on 'Biliary tract manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22521?source=see_link\">",
"     \"Clinical manifestations and diagnosis of primary sclerosing cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16601951\">",
"    <span class=\"h2\">",
"     Salivary and lacrimal gland involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salivary gland involvement is a common feature of IgG4-RD. Patients may present with enlargement of lacrimal and salivary glands (parotid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    submandibular) or with chronic sclerosing sialadenitis and unilateral or bilateral submandibular gland enlargement [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/36\">",
"     36",
"    </a>",
"    ]. These entities were previously called Mikulicz disease (or syndrome) and K&uuml;ttner tumor, respectively, and were often erroneously considered to be subcategories of Sj&ouml;gren's syndrome (SS) (",
"    <a class=\"graphic graphic_picture graphicRef56827 \" href=\"UTD.htm?0/42/672\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/11,20,36-41\">",
"     11,20,36-41",
"    </a>",
"    ]. Many of the patients previously described as having SS in association with AIP and IgG4-RD may have had one of these conditions rather than true SS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link&amp;anchor=H3#H3\">",
"     \"Classification and diagnosis of Sj&ouml;gren's syndrome\", section on 'Mikulicz syndrome and IgG4-related disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9927?source=see_link\">",
"     \"Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nearly 40 percent of patients with IgG4-related pancreatitis also have salivary or lacrimal gland involvement, while AIP may be seen in only 17 percent of patients presenting with sialadenitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/11,27\">",
"     11,27",
"    </a>",
"    ]. Sialadenitis often presents prior to AIP in patients who develop both conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/42\">",
"     42",
"    </a>",
"    ]. Unlike AIP and other forms of IgG4-RD, patients with salivary and lacrimal involvement include comparable numbers of both men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The pathologic findings are typical of those in other patients with IgG4-RD, including the lymphoplasmacytic infiltrate with IgG4-positive cells, sometimes with obliterative phlebitis and fibrosis (",
"    <a class=\"graphic graphic_picture graphicRef76311 \" href=\"UTD.htm?29/20/30025\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef67582 \" href=\"UTD.htm?39/26/40361\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/12\">",
"     12",
"    </a>",
"    ]. Increased IgG4 and IgE serum levels are also present. These histopathologic and laboratory findings distinguish IgG4-related sialadenitis from SS. Low complement levels may be seen in either condition.",
"   </p>",
"   <p>",
"    The clinical features that characterize IgG4-related sialadenitis and also distinguish it from SS include [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fewer patients with dry mouth, dry eyes, or arthralgias (38, 33, and 16 percent versus 87, 94, and 48 percent, respectively). Despite marked lacrimal and salivary gland enlargement, these patients experience relatively mild dryness of the eyes and of the mouth.",
"     </li>",
"     <li>",
"      A higher frequency of allergic rhinitis and bronchial asthma (41 and 14 percent versus 7 and 3 percent, respectively)",
"     </li>",
"     <li>",
"      A higher frequency of AIP and interstitial nephritis (17 and 17 percent versus 0 and 7 percent, respectively)",
"     </li>",
"     <li>",
"      Low frequencies of autoantibodies, including rheumatoid factor, antinuclear antibodies, anti-SSA, and anti-SSB (27, 23, 2, and 0 percent versus 87, 90, 100, and 100 percent, respectively)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with IgG4-related ophthalmic disease, primarily involving the lacrimal gland (IgG4-related dacryoadenitis), have also been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Many exhibited bilateral involvement, and concurrent salivary gland involvement was common. Histologic and serologic findings are similar to those seen in patients with sialadenitis and in other tissues, although obliterative phlebitis is usually absent. IgG4-RD also appears to account for 25 to 50 percent of orbital pseudotumors and is additionally recognized now as a cause of orbital myositis (IgG4-related orbital myositis) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not certain whether IgG4-RD predisposes to the development of ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphomas or other lymphomas, but several cases have been reported that have raised this concern [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. Additional study is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179281615\">",
"    <span class=\"h2\">",
"     Retroperitoneal fibrosis and related disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;In several small case series, a variable proportion of patients with idiopathic retroperitoneal fibrosis exhibits histologic and serologic changes consistent with IgG4-RD [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/50-53\">",
"     50-53",
"    </a>",
"    ]. Chronic inflammatory and fibrotic change may be present and can involve regional tissues; it may cause an obstructive uropathy. In some cases, the syndrome is responsive to glucocorticoids. The diagnosis of IgG4-RD in this setting can be challenging because of the advanced fibrotic changes typically observed in this condition. Retroperitoneal fibrosis is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34136?source=see_link\">",
"     \"Clinical manifestations and diagnosis of retroperitoneal fibrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/35/14904?source=see_link\">",
"     \"Treatment of retroperitoneal fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All 14 of the reported cases of IgG4-related retroperitoneal fibrosis in one report exhibited involvement of other organs, including the pancreas (11 patients), salivary glands (3 patients), lymph nodes (2 patients), one affecting the pituitary gland, and one with mediastinal periaortitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/53\">",
"     53",
"    </a>",
"    ]. However, cases of isolated IgG4-related retroperitoneal fibrosis have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cases of patients with sclerosing mesenteritis, sclerosing mediastinitis, and multifocal fibrosclerosis have also been reported associated with IgG4-RD [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14440?source=see_link&amp;anchor=H5#H5\">",
"     \"Sclerosing mesenteritis\", section on 'Autoimmunity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15526?source=see_link&amp;anchor=H5#H5\">",
"     \"Fibrosing mediastinitis\", section on 'Other precipitants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179281773\">",
"    <span class=\"h2\">",
"     Aortitis and periaortitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgG4-RD has been recognized as one of the causes of noninfectious aortitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/53\">",
"     53",
"    </a>",
"    ]. A series of patients with thoracic lymphoplasmacytic aortitis or with inflammatory abdominal aortic aneurysms and abdominal periaortitis has been identified in retrospective pathologic studies of patients who had undergone aortic resections [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/53,58,59\">",
"     53,58,59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11450?source=see_link&amp;anchor=H1428675#H1428675\">",
"     \"Epidemiology, risk factors, pathogenesis and natural history of abdominal aortic aneurysm\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22712?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical features and diagnosis of thoracic aortic aneurysm\", section on 'Etiology and pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IgG4-related thoracic aortitis &mdash; In a study of 638 patients who underwent thoracic aortic resection over a five-year period in a North American hospital, three of four patients with lymphoplasmacytic aortitis exhibited histology characteristic of IgG4-RD [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/58\">",
"       58",
"      </a>",
"      ]. These three patients represented 9 percent of the 33 cases identified in the study with noninfectious aortitis or 0.5 percent of the entire series of thoracic aortic resections. These three patients and three other reported patients were all men between the ages of 65 and 74 [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/53\">",
"       53",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Similarly, in a series of 125 patients reported from a hospital in Japan, two patients with IgG4-related aortitis were identified among 120 patients with thoracic aortic resections (1.6 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/60\">",
"       60",
"      </a>",
"      ]. Three additional patients with atherosclerotic changes and without extra-aortic involvement by IgG4-RD also had similar infiltrates of IgG4-positive plasma cells. Whether patients with prominent atherosclerotic changes should also be included among patients with IgG4-RD remains uncertain [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/53,60\">",
"       53,60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IgG4-related abdominal aortitis &mdash; Four of 10 patients with inflammatory abdominal aortic aneurysms identified at a medical center in Japan over a 15-year period had findings consistent with IgG4-RD, including infiltration with IgG4 positive plasma cells and elevated serum levels of IgG4 [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/59\">",
"       59",
"      </a>",
"      ]. Patients ranged in age from 58 to 72 years. Inflammatory abdominal aortitis may be associated with retroperitoneal fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H360095760\">",
"    <span class=\"h2\">",
"     Thyroid disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two forms of thyroid involvement in IgG4-RD have been described, including Reidel&rsquo;s thyroiditis (IgG4-related thyroid disease) and the fibrous variant of Hashimoto&rsquo;s thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Reidel&rsquo;s thyroiditis is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/15/43257?source=see_link&amp;anchor=H2#H2\">",
"     \"Infiltrative thyroid disease\", section on 'Riedel's thyroiditis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H360096128\">",
"    <span class=\"h2\">",
"     Lung and pleural disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple reports have documented IgG4-related pulmonary disease, which may be asymptomatic or present with cough, hemoptysis, dyspnea, pleurisy, or chest pain; pseudotumors and interstitial pneumonia have been associated with AIP [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/63-67\">",
"     63-67",
"    </a>",
"    ]. Visceral or parietal pleural thickening may occur. The affected tissues exhibit characteristic lymphoplasmacytic infiltrates enriched in IgG4-positive plasma cells. Obliterative arteritis is more common in the lung than in other organs affected by IgG4-RD [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/12\">",
"     12",
"    </a>",
"    ]. Four patterns of lung involvement have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Solid nodular",
"     </li>",
"     <li>",
"      Bronchovascular",
"     </li>",
"     <li>",
"      Alveolar interstitial (with honeycombing, bronchiectasis, and diffuse ground-glass opacities)",
"     </li>",
"     <li>",
"      Round-shaped ground-glass opacities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    IgG4-RD may mimic sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. In one study of patients suspected of having sarcoid with bilateral hilar adenopathy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lung nodules on computerized tomography (CT) of the chest, patients with IgG4-RD were identified among a subset with elevated serum IgG4; they exhibited significantly higher levels of bronchoalveolar lavage IgG4,",
"    <span class=\"nowrap\">",
"     IgG4/IgG,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     IgG4/IgG3",
"    </span>",
"    compared with those with normal serum IgG4 levels [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interstitial pneumonitis associated with IgG4-RD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/32/16906?source=see_link&amp;anchor=H327683#H327683\">",
"     \"Interstitial lung disease associated with Sj&ouml;gren's syndrome: Clinical manifestations, evaluation, and diagnosis\", section on 'IgG4-related systemic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16601972\">",
"    <span class=\"h2\">",
"     Tubulointerstitial nephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individual cases and case series have described renal involvement in patients with IgG4-RD; the most common finding is tubulointerstitial nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/71-74\">",
"     71-74",
"    </a>",
"    ]. Affected patients are primarily middle-aged and older men, and histopathology and other laboratory characteristics are similar to those observed in patients with autoimmune pancreatitis (AIP) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/74\">",
"     74",
"    </a>",
"    ]. The histologic findings include lymphoplasmacytic infiltration of the renal interstitium with increased numbers of IgG4-positive plasma cells and the presence of fibrosis. Nodular lesions mimicking renal carcinoma may be seen.",
"   </p>",
"   <p>",
"    In a study of 153 patients with suspected IgG4-related disease, retrospectively collected from multiple medical centers in Japan, 23 patients (15 percent) were identified with tubulointerstitial nephritis (TIN) secondary to IgG4-RD, all but one of whom (96 percent of TIN patients) exhibited involvement of other organs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/74\">",
"     74",
"    </a>",
"    ]. These extrarenal manifestations included sialadenitis (83 percent), lymphadenopathy (44 percent), AIP (39 percent), dacryoadenitis (30 percent), lung lesions (26 percent), and others in individual patients. In addition to TIN, 3 of the 23 patients also had mild mesangioproliferative glomerulonephritis, and one each had findings of membranous nephropathy and of focal segmental endocapillary hypercellularity.",
"   </p>",
"   <p>",
"    Symptoms were usually associated with the extrarenal manifestations, rather than the renal abnormalities, although edema was seen in two patients. Renal changes were recognized due to urinary abnormalities, renal dysfunction,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    imaging abnormalities, including renal parenchymal lesions on computerized tomography and increased renal uptake with gallium citrate scintigraphy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H360095919\">",
"    <span class=\"h2\">",
"     Other involved organs and tissues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of other organs and tissues by IgG4-RD, which has been described in additional case reports and small case series, includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Skin disease, including a subset of cutaneous pseudolymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/75,76\">",
"       75,76",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      IgG4-hepatopathy, resembling autoimmune hepatitis, and hepatic inflammatory pseudotumor [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/77,78\">",
"       77,78",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Lymphoplasmacytic gastritis associated with autoimmune pancreatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/79\">",
"       79",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Sclerosing mastitis and inflammatory pseudotumors of the breast [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/80,81\">",
"       80,81",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hypopituitarism with IgG4-related hypophysitis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/82,83\">",
"       82,83",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pachymeningitis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/84\">",
"       84",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Prostatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/85\">",
"       85",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Constrictive pericarditis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/3,86,87\">",
"       3,86,87",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34249877\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of IgG4-RD is based upon biopsy findings demonstrating the characteristic histopathologic findings and immunohistochemical staining. These findings include lymphoplasmacytic tissue infiltration of mainly IgG4-positive plasma cells and small lymphocytes, accompanied by fibrosis that has storiform features and often by obliterative phlebitis. A modest tissue eosinophilia is often present. Serum IgG4 levels should be measured, and isolated elevated levels are a significant aid in diagnosis, although they are not diagnostic. The histopathological and immunohistochemical staining features of IgG4-RD are strikingly similar in different tissues, regardless of the organ or tissue involved. (See",
"    <a class=\"local\" href=\"#H1086624\">",
"     'Diagnostic criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H447315085\">",
"    <span class=\"h2\">",
"     Indications for diagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility of IgG4-RD should be considered in patients with one of the characteristic patterns of organ or tissue involvement. (See",
"    <a class=\"local\" href=\"#H250672027\">",
"     'IgG4-RD associated disorders'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients at high risk for having IgG4-RD are those with any of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pancreatitis of unknown origin",
"     </li>",
"     <li>",
"      Sclerosing cholangitis",
"     </li>",
"     <li>",
"      Bilateral salivary",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lacrimal gland enlargement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The likelihood of IgG4-RD for patients presenting with at least one of these conditions is significantly increased if high serum levels of IgG4, allergic symptoms,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other fibrotic processes, such as retroperitoneal fibrosis, are also present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H447315093\">",
"    <span class=\"h2\">",
"     Diagnostic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of IgG4-RD requires characteristic findings upon biopsy of affected tissue, but additional organ involvement may be possible to identify through a careful history, physical examination, routine laboratory testing, and selected imaging studies. (See",
"    <a class=\"local\" href=\"#H16601923\">",
"     'Clinical manifestations'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H34249877\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We obtain the following testing for establishing the initial diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tissue biopsy &mdash; The specific procedure depends upon what target organ will be biopsied and whether a discrete mass is present. A needle biopsy is often but not always adequate [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/7,12\">",
"       7,12",
"      </a>",
"      ]. In the presence of abnormal histopathology characteristic of the syndrome, we generally do not perform additional needle or excisional biopsies of other tissues which may be affected, particularly if improvement in these other areas has occurred with glucocorticoid treatment.",
"     </li>",
"     <li>",
"      Serum IgG4 &mdash; The serum IgG4 level was elevated above the upper limit of normal (&gt;135",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      in 86 percent of 114 patients in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/12\">",
"       12",
"      </a>",
"      ]. The degree of IgG4 elevation may correlate with disease activity and the number of involved organs and usually decreases after treatment with glucocorticoids [",
"      <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/7,88\">",
"       7,88",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1086624\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;A consensus statement from a multinational, multidisciplinary group of experts on IgG4-RD describes guidelines for the diagnosis of the disease and the histopathologic findings important in making the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/89\">",
"     89",
"    </a>",
"    ]. Well-defined diagnostic criteria had previously been proposed only for autoimmune pancreatitis (AIP). The histopathological findings of a dense lymphoplasmacytic infiltrate, storiform fibrosis, and obliterative phlebitis are critical features for establishing the diagnosis in affected tissues other than lymph nodes (",
"    <a class=\"graphic graphic_picture graphicRef76767 \" href=\"UTD.htm?13/25/13721\">",
"     picture 1",
"    </a>",
"    ). The presence of these findings, often together with mild tissue eosinophilia, is strongly suggestive if accompanied by increased numbers of IgG4-positive plasma cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40168?source=see_link&amp;anchor=H7#H7\">",
"     \"Autoimmune pancreatitis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The number of IgG4-positive plasma cells per high power field (HPF) regarded as sufficient varies somewhat from tissue to tissue, and tissue IgG4-positive cell counts and the ratios of IgG4- to IgG-positive cells are considered secondary in importance [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/3,7,12,38,89\">",
"     3,7,12,38,89",
"    </a>",
"    ]. Generally, the minimum for making the diagnosis for most tissues is from 30 to 50 IgG4-positive",
"    <span class=\"nowrap\">",
"     cells/HPF.",
"    </span>",
"    However, in some organs or tissues, including the kidney and others, only 10 IgG4-positive plasma",
"    <span class=\"nowrap\">",
"     cells/HPF",
"    </span>",
"    may be sufficient.",
"   </p>",
"   <p>",
"    The diagnosis cannot be predicated entirely upon the number of IgG4-positive plasma cells, because a large number of other entities can have such cells, nor can the diagnosis of IgG4-RD be based upon serum concentrations of IgG4 alone. Serum IgG4 concentrations are neither sufficiently sensitive nor specific for this disease. Thus, we strongly prefer confirmation of the diagnosis by biopsy of an involved organ whenever this is possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11899728\">",
"    <span class=\"h2\">",
"     Postdiagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;We obtain the following testing for establishing the extent of disease following the initial diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Imaging studies &mdash;We generally obtain a computed tomography scan of the chest, abdomen, and pelvis in patients diagnosed with IgG4-RD, because of the frequency of subclinical disease. Selected patients require additional imaging studies, particularly if disease in the orbits is suspected. Where available, positron emission tomographic (PET) scanning can also be highly effective in determining the extent of disease and should be considered at baseline.",
"     </li>",
"     <li>",
"      Urinalysis &mdash; Asymptomatic proteinuria may be an indication of subclinical IgG4-related tubulointerstitial nephritis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34249908\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of IgG4-related disease is broad and depends upon the specific site of involvement and clinical presentation (see appropriate heading above and see appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43795020\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment for IgG4-related disease (IgG4-RD) has not been established. Our approach to treatment of IgG4-RD is based upon observational data, including case reports and case series, almost all of which have focused on patients with autoimmune pancreatitis (AIP), and upon our clinical experience with patients with other forms of IgG4-RD [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/90\">",
"     90",
"    </a>",
"    ]. There are no randomized trials that have evaluated approaches to the treatment of IgG4-RD or type 1 AIP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40168?source=see_link&amp;anchor=H13#H13\">",
"     \"Autoimmune pancreatitis\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40168?source=see_link&amp;anchor=H14#H14\">",
"     \"Autoimmune pancreatitis\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients respond to glucocorticoids within several weeks, typically with symptomatic improvement, reductions in the size of masses or organ enlargement, improvement in organ function, and often a decrease in serum levels of IgG4. However, some require a few months to respond, and there are some patients who relapse and others who respond less well or not at all initially. Those who respond less well may include patients with more advanced fibrotic changes, but these patients have not been well-defined. A responder index is under development for use in clinical research to assess patient outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/91\">",
"     91",
"    </a>",
"    ]. The treatment of AIP and the evidence supporting the use of these therapies is discussed in detail elsewhere.",
"   </p>",
"   <p>",
"    Patients who are symptomatic from their organ involvement at the time of the diagnosis often benefit from treatment. Examples of such symptomatic involvement include patients with lacrimal gland swelling or other orbital pseudotumors, who may have significant proptosis; those with submandibular or parotid gland swelling, who may have pain from their glandular enlargement or concern about cosmetic issues; those with renal involvement, who may have kidney dysfunction due to tubulointerstitial nephritis; and those with type I autoimmune pancreatitis (AIP) or retroperitoneal fibrosis, who may have abdominal or flank pain or other manifestations of their organ involvement. All of these patients need to be treated. In contrast, for a subset of patients such as those who have mild lymphadenopathy or incidentally-detected lung nodules, watchful waiting may be appropriate.",
"   </p>",
"   <p>",
"    We suggest beginning treatment with orally administered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , usually at a dose of approximately 40",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    A response is frequently seen within two to four weeks. Once a significant response is clinically evident in the affected organ system, we begin to gradually taper the dose of glucocorticoids, with a planned reduction over a two-month period, as tolerated, with the goal of discontinuing the medication.",
"   </p>",
"   <p>",
"    In patients who are resistant to glucocorticoids or who are unable to have their dose reduced sufficiently (usually to below 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) to avoid adverse effects of the medication due to chronic use, we use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (up to 2.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    as tolerated). However, the effects of these glucocorticoid-sparing medications in IgG4-RD have not been evaluated adequately to clearly define their role relative to other agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40168?source=see_link&amp;anchor=H13#H13\">",
"     \"Autoimmune pancreatitis\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40168?source=see_link&amp;anchor=H16#H16\">",
"     \"Autoimmune pancreatitis\", section on 'Immunomodulatory drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    B cell depletion therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    is an effective treatment in many of the patients with disease that is refractory to glucocorticoids and other medications [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/90,92,93\">",
"     90,92,93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43795028\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of IgG4-RD has not been well-defined; some patients improve spontaneously without treatment, but many relapse in time [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/7,90\">",
"     7,90",
"    </a>",
"    ]. Causes of significant morbidity and mortality in untreated patients include cirrhosis and portal hypertension; retroperitoneal fibrosis; complications from aortic aneurysms, including dissection; biliary obstruction; diabetes mellitus; and others [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/51,58,90,94,95\">",
"     51,58,90,94,95",
"    </a>",
"    ]. Sustained benefit may be observed in treated patients, but relapses are common after discontinuation of therapy. Additional organs and tissues may become involved over time, sometimes despite apparently effective treatment. Additional studies of long term prognosis are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H447315657\">",
"    <span class=\"h2\">",
"     Risk of malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several types of lymphoma have been reported in patients with IgG4-RD, both in Japan and in North America [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/7,43,47,96,97\">",
"     7,43,47,96,97",
"    </a>",
"    ]. In the study in North America, which involved 111 patients with IgG4-RD (91 percent with AIP), three cases of non-Hodgkin lymphoma were found three to five years after the diagnosis of IgG-RD [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/47\">",
"     47",
"    </a>",
"    ]. The standardized incidence ratio was 16.0 (95% CI 3.3-45.5), suggesting an increased risk of non-Hodgkin lymphoma among this group of patients referred to an academic medical center with special interest in this disorder. Further studies are required to better define the degree of risk and the effect of treatment upon such risk, if present.",
"   </p>",
"   <p>",
"    Several cases of pancreatic cancer and cases of salivary duct carcinoma, pulmonary adenocarcinoma, small cell carcinoma of the lung, and gastrointestinal clear cell sarcoma have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?12/55/13178/abstract/7\">",
"     7",
"    </a>",
"    ]. Additional study is required to determine the degree, if any, of increased risk for these and other malignancies in affected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43795036\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IgG4-related systemic disease (IgG4-RD) is an increasingly recognized syndrome of unknown etiology, most often occurring in middle-aged and older men, which is comprised of a collection of disorders that share specific pathologic, serologic, and clinical features. Several of the manifestations typically occur in the same patient; these findings were previously thought to be unrelated and include (see",
"      <a class=\"local\" href=\"#H16601923\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H250672027\">",
"       'IgG4-RD associated disorders'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis (see",
"      <a class=\"local\" href=\"#H16601930\">",
"       'Autoimmune pancreatitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16601937\">",
"       'IgG4-related sclerosing cholangitis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40168?source=see_link\">",
"       \"Autoimmune pancreatitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mikulicz&rsquo;s disease and sclerosing sialadenitis (K&uuml;ttner&rsquo;s tumor), inflammatory orbital pseudotumor, and chronic sclerosing dacryoadenitis (see",
"      <a class=\"local\" href=\"#H16601951\">",
"       'Salivary and lacrimal gland involvement'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Idiopathic retroperitoneal fibrosis and related disorders (see",
"      <a class=\"local\" href=\"#H179281615\">",
"       'Retroperitoneal fibrosis and related disorders'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Chronic sclerosing aortitis and periaortitis (see",
"      <a class=\"local\" href=\"#H179281773\">",
"       'Aortitis and periaortitis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Riedel&rsquo;s thyroiditis and a subset of Hashimoto&rsquo;s thyroiditis (see",
"      <a class=\"local\" href=\"#H360095760\">",
"       'Thyroid disease'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      IgG4-related interstitial pneumonitis and pulmonary inflammatory pseudotumors (see",
"      <a class=\"local\" href=\"#H360096128\">",
"       'Lung and pleural disease'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      IgG4-related tubulointerstitial nephritis (see",
"      <a class=\"local\" href=\"#H16601972\">",
"       'Tubulointerstitial nephritis'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The hallmarks of IgG4-RD are lymphoplasmacytic tissue infiltration of mainly IgG4-positive plasma cells and small lymphocytes, which may be accompanied by sclerosis, by obliterative phlebitis, and, in the majority of patients, by elevated serum levels of IgG4. Patients often present with subacute development of a mass in the affected organ or diffuse enlargement of an organ. Lymphadenopathy is common, and symptoms of asthma or allergy may be present. A good initial therapeutic response to glucocorticoids is also characteristic. (See",
"      <a class=\"local\" href=\"#H4739538\">",
"       'Definition and histology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H365938\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H250672034\">",
"       'Lymphadenopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of IgG4-RD is based upon biopsy findings demonstrating the characteristic histopathology. Serum IgG4 levels should be measured, and isolated elevated levels are a significant aid in diagnosis, although they are not diagnostic. Additional organ involvement may be identified through a careful history, physical examination, routine laboratory testing, and selected imaging studies. (See",
"      <a class=\"local\" href=\"#H34249877\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H447315085\">",
"       'Indications for diagnostic evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H447315093\">",
"       'Diagnostic studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest beginning treatment with glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We generally initiate therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (40",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      which is then tapered as tolerated over a two-month period. Responses are characterized by symptomatic improvement, reductions in the size of masses or organ enlargement, improvement in organ function, and often a decrease in serum levels of IgG4. In patients who do not respond to up to 40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of prednisone or who cannot be tapered to less than 10 mg daily, we use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil. We treat patients resistant to these therapies with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H43795020\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40168?source=see_link&amp;anchor=H13#H13\">",
"       \"Autoimmune pancreatitis\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The natural history and prognosis are not well-described. Spontaneous improvement can be seen, but disease often recurs without treatment. Most patients respond initially to therapy with glucocorticoids, but relapses are common following discontinuation of therapy. Significant organ dysfunction may arise from uncontrolled and progressive inflammatory and fibrotic changes in affected tissues. The possibility of increased risk of malignancy in patients with IgG4-RD requires further study. (See",
"      <a class=\"local\" href=\"#H43795028\">",
"       'Prognosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H447315657\">",
"       'Risk of malignancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/1\">",
"      Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 2012; 366:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/2\">",
"      Kamisawa T, Funata N, Hayashi Y, et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol 2003; 38:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/3\">",
"      Khosroshahi A, Stone JH. A clinical overview of IgG4-related systemic disease. Curr Opin Rheumatol 2011; 23:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/4\">",
"      Okazaki K, Uchida K, Koyabu M, et al. Recent advances in the concept and diagnosis of autoimmune pancreatitis and IgG4-related disease. J Gastroenterol 2011; 46:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/5\">",
"      Stone JH, Khosroshahi A, Deshpande V, et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum 2012; 64:3061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/6\">",
"      Umehara H, Okazaki K, Masaki Y, et al. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol 2012; 22:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/7\">",
"      Cheuk W, Chan JK. IgG4-related sclerosing disease: a critical appraisal of an evolving clinicopathologic entity. Adv Anat Pathol 2010; 17:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/8\">",
"      Deheragoda MG, Church NI, Rodriguez-Justo M, et al. The use of immunoglobulin g4 immunostaining in diagnosing pancreatic and extrapancreatic involvement in autoimmune pancreatitis. Clin Gastroenterol Hepatol 2007; 5:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/9\">",
"      Okazaki K, Chiba T. Autoimmune related pancreatitis. Gut 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/10\">",
"      Smyrk TC. Pathological features of IgG4-related sclerosing disease. Curr Opin Rheumatol 2011; 23:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/11\">",
"      Masaki Y, Dong L, Kurose N, et al. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis 2009; 68:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/12\">",
"      Zen Y, Nakanuma Y. IgG4-related disease: a cross-sectional study of 114 cases. Am J Surg Pathol 2010; 34:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/13\">",
"      Ota M, Katsuyama Y, Hamano H, et al. Two critical genes (HLA-DRB1 and ABCF1)in the HLA region are associated with the susceptibility to autoimmune pancreatitis. Immunogenetics 2007; 59:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/14\">",
"      Deshpande V, Chicano S, Chiocca S, et al. Autoimmune pancreatitis: a systemic immune complex mediated disease. Am J Surg Pathol 2006; 30:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/15\">",
"      Zen Y, Fujii T, Harada K, et al. Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology 2007; 45:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/16\">",
"      Miyoshi H, Uchida K, Taniguchi T, et al. Circulating na&iuml;ve and CD4+CD25high regulatory T cells in patients with autoimmune pancreatitis. Pancreas 2008; 36:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/17\">",
"      Bj&ouml;rnsson E. Immunoglobulin G4-associated cholangitis. Curr Opin Gastroenterol 2008; 24:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/18\">",
"      Bateman AC, Deheragoda MG. IgG4-related systemic sclerosing disease - an emerging and under-diagnosed condition. Histopathology 2009; 55:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/19\">",
"      Okazaki K, Uchida K, Ohana M, et al. Autoimmune-related pancreatitis is associated with autoantibodies and a Th1/Th2-type cellular immune response. Gastroenterology 2000; 118:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/20\">",
"      Fragoulis GE, Moutsopoulos HM. IgG4 syndrome: old disease, new perspective. J Rheumatol 2010; 37:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/21\">",
"      Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy 2009; 39:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/22\">",
"      Liu LJ, Chen M, Yu F, et al. IgG subclass distribution, affinity of anti-myeloperoxidase antibodies in sera from patients with Wegener's granulomatosis and microscopic polyangiitis. Nephrology (Carlton) 2008; 13:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/23\">",
"      Zen Y, Nakanuma Y. Pathogenesis of IgG4-related disease. Curr Opin Rheumatol 2011; 23:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/24\">",
"      Jeannin P, Delneste Y, Lecoanet-Henchoz S, et al. Interleukin-7 (IL-7) enhances class switching to IgE and IgG4 in the presence of T cells via IL-9 and sCD23. Blood 1998; 91:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/25\">",
"      Takahashi H, Yamamoto M, Suzuki C, et al. The birthday of a new syndrome: IgG4-related diseases constitute a clinical entity. Autoimmun Rev 2010; 9:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/26\">",
"      Sah RP, Chari ST, Pannala R, et al. Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology 2010; 139:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/27\">",
"      Hamano H, Arakura N, Muraki T, et al. Prevalence and distribution of extrapancreatic lesions complicating autoimmune pancreatitis. J Gastroenterol 2006; 41:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/28\">",
"      Cheuk W, Yuen HK, Chu SY, et al. Lymphadenopathy of IgG4-related sclerosing disease. Am J Surg Pathol 2008; 32:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/29\">",
"      Saegusa H, Momose M, Kawa S, et al. Hilar and pancreatic gallium-67 accumulation is characteristic feature of autoimmune pancreatitis. Pancreas 2003; 27:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/30\">",
"      Sato Y, Kojima M, Takata K, et al. Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman's disease. Mod Pathol 2009; 22:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/31\">",
"      Sato Y, Kojima M, Takata K, et al. Multicentric Castleman's disease with abundant IgG4-positive cells: a clinical and pathological analysis of six cases. J Clin Pathol 2010; 63:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/32\">",
"      Nishimori I, Tamakoshi A, Otsuki M, Research Committee on Intractable Diseases of the Pancreas, Ministry of Health, Labour, and Welfare of Japan. Prevalence of autoimmune pancreatitis in Japan from a nationwide survey in 2002. J Gastroenterol 2007; 42 Suppl 18:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/33\">",
"      Shimosegawa T, Kanno A. Autoimmune pancreatitis in Japan: overview and perspective. J Gastroenterol 2009; 44:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/34\">",
"      Ghazale A, Chari ST, Smyrk TC, et al. Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. Am J Gastroenterol 2007; 102:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/35\">",
"      Webster GJ, Pereira SP, Chapman RW. Autoimmune pancreatitis/IgG4-associated cholangitis and primary sclerosing cholangitis--overlapping or separate diseases? J Hepatol 2009; 51:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/36\">",
"      Geyer JT, Deshpande V. IgG4-associated sialadenitis. Curr Opin Rheumatol 2011; 23:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/37\">",
"      Yamamoto M, Takahashi H, Sugai S, Imai K. Clinical and pathological characteristics of Mikulicz's disease (IgG4-related plasmacytic exocrinopathy). Autoimmun Rev 2005; 4:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/38\">",
"      Masaki Y, Sugai S, Umehara H. IgG4-related diseases including Mikulicz's disease and sclerosing pancreatitis: diagnostic insights. J Rheumatol 2010; 37:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/39\">",
"      Stone JH, Caruso PA, Deshpande V. Case records of the Massachusetts General Hospital. Case 24-2009. A 26-year-old woman with painful swelling of the neck. N Engl J Med 2009; 361:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/40\">",
"      Khosroshahi A, Stone JH. IgG4-related systemic disease: the age of discovery. Curr Opin Rheumatol 2011; 23:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/41\">",
"      Geyer JT, Ferry JA, Harris NL, et al. Chronic sclerosing sialadenitis (K&uuml;ttner tumor) is an IgG4-associated disease. Am J Surg Pathol 2010; 34:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/42\">",
"      Kubota K, Wada T, Kato S, et al. Highly active state of autoimmune pancreatitis with mikulicz disease. Pancreas 2010; 39:e6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/43\">",
"      Sato Y, Ohshima K, Ichimura K, et al. Ocular adnexal IgG4-related disease has uniform clinicopathology. Pathol Int 2008; 58:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/44\">",
"      Cheuk W, Yuen HK, Chan JK. Chronic sclerosing dacryoadenitis: part of the spectrum of IgG4-related Sclerosing disease? Am J Surg Pathol 2007; 31:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/45\">",
"      Mehta M, Jakobiec F, Fay A. Idiopathic fibroinflammatory disease of the face, eyelids, and periorbital membrane with immunoglobulin G4-positive plasma cells. Arch Pathol Lab Med 2009; 133:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/46\">",
"      Wallace ZS, Khosroshahi A, Jakobiec FA, et al. IgG4-related systemic disease as a cause of \"idiopathic\" orbital inflammation, including orbital myositis, and trigeminal nerve involvement. Surv Ophthalmol 2012; 57:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/47\">",
"      Takahashi N, Ghazale AH, Smyrk TC, et al. Possible association between IgG4-associated systemic disease with or without autoimmune pancreatitis and non-Hodgkin lymphoma. Pancreas 2009; 38:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/48\">",
"      Ochoa ER, Harris NL, Pilch BZ. Marginal zone B-cell lymphoma of the salivary gland arising in chronic sclerosing sialadenitis (K&uuml;ttner tumor). Am J Surg Pathol 2001; 25:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/49\">",
"      Sato Y, Takata K, Ichimura K, et al. IgG4-producing marginal zone B-cell lymphoma. Int J Hematol 2008; 88:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/50\">",
"      Neild GH, Rodriguez-Justo M, Wall C, Connolly JO. Hyper-IgG4 disease: report and characterisation of a new disease. BMC Med 2006; 4:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/51\">",
"      Zen Y, Onodera M, Inoue D, et al. Retroperitoneal fibrosis: a clinicopathologic study with respect to immunoglobulin G4. Am J Surg Pathol 2009; 33:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/52\">",
"      Hamano H, Kawa S, Ochi Y, et al. Hydronephrosis associated with retroperitoneal fibrosis and sclerosing pancreatitis. Lancet 2002; 359:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/53\">",
"      Stone JR. Aortitis, periaortitis, and retroperitoneal fibrosis, as manifestations of IgG4-related systemic disease. Curr Opin Rheumatol 2011; 23:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/54\">",
"      Zen Y, Sawazaki A, Miyayama S, et al. A case of retroperitoneal and mediastinal fibrosis exhibiting elevated levels of IgG4 in the absence of sclerosing pancreatitis (autoimmune pancreatitis). Hum Pathol 2006; 37:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/55\">",
"      Chen TS, Montgomery EA. Are tumefactive lesions classified as sclerosing mesenteritis a subset of IgG4-related sclerosing disorders? J Clin Pathol 2008; 61:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/56\">",
"      Taniguchi T, Kobayashi H, Fukui S, et al. A case of multifocal fibrosclerosis involving posterior mediastinal fibrosis, retroperitoneal fibrosis, and a left seminal vesicle with elevated serum IgG4. Hum Pathol 2006; 37:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/57\">",
"      Hamed G, Tsushima K, Yasuo M, et al. Inflammatory lesions of the lung, submandibular gland, bile duct and prostate in a patient with IgG4-associated multifocal systemic fibrosclerosis. Respirology 2007; 12:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/58\">",
"      Stone JH, Khosroshahi A, Deshpande V, Stone JR. IgG4-related systemic disease accounts for a significant proportion of thoracic lymphoplasmacytic aortitis cases. Arthritis Care Res (Hoboken) 2010; 62:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/59\">",
"      Kasashima S, Zen Y, Kawashima A, et al. Inflammatory abdominal aortic aneurysm: close relationship to IgG4-related periaortitis. Am J Surg Pathol 2008; 32:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/60\">",
"      Kasashima S, Zen Y, Kawashima A, et al. A clinicopathologic study of immunoglobulin G4-related sclerosing disease of the thoracic aorta. J Vasc Surg 2010; 52:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/61\">",
"      Li Y, Nishihara E, Kakudo K. Hashimoto's thyroiditis: old concepts and new insights. Curr Opin Rheumatol 2011; 23:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/62\">",
"      Li Y, Nishihara E, Hirokawa M, et al. Distinct clinical, serological, and sonographic characteristics of hashimoto's thyroiditis based with and without IgG4-positive plasma cells. J Clin Endocrinol Metab 2010; 95:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/63\">",
"      Taniguchi T, Ko M, Seko S, et al. Interstitial pneumonia associated with autoimmune pancreatitis. Gut 2004; 53:770; author reply 770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/64\">",
"      Zen Y, Kitagawa S, Minato H, et al. IgG4-positive plasma cells in inflammatory pseudotumor (plasma cell granuloma) of the lung. Hum Pathol 2005; 36:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/65\">",
"      Yamashita K, Haga H, Kobashi Y, et al. Lung involvement in IgG4-related lymphoplasmacytic vasculitis and interstitial fibrosis: report of 3 cases and review of the literature. Am J Surg Pathol 2008; 32:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/66\">",
"      Shrestha B, Sekiguchi H, Colby TV, et al. Distinctive pulmonary histopathology with increased IgG4-positive plasma cells in patients with autoimmune pancreatitis: report of 6 and 12 cases with similar histopathology. Am J Surg Pathol 2009; 33:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/67\">",
"      Zen Y, Inoue D, Kitao A, et al. IgG4-related lung and pleural disease: a clinicopathologic study of 21 cases. Am J Surg Pathol 2009; 33:1886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/68\">",
"      Inoue D, Zen Y, Abo H, et al. Immunoglobulin G4-related lung disease: CT findings with pathologic correlations. Radiology 2009; 251:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/69\">",
"      Tsushima K, Yokoyama T, Kawa S, et al. Elevated IgG4 levels in patients demonstrating sarcoidosis-like radiologic findings. Medicine (Baltimore) 2011; 90:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/70\">",
"      Tsushima K, Tanabe T, Yamamoto H, et al. Pulmonary involvement of autoimmune pancreatitis. Eur J Clin Invest 2009; 39:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/71\">",
"      Rudmik L, Trpkov K, Nash C, et al. Autoimmune pancreatitis associated with renal lesions mimicking metastatic tumours. CMAJ 2006; 175:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/72\">",
"      Murashima M, Tomaszewski J, Glickman JD. Chronic tubulointerstitial nephritis presenting as multiple renal nodules and pancreatic insufficiency. Am J Kidney Dis 2007; 49:e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/73\">",
"      Watson SJ, Jenkins DA, Bellamy CO. Nephropathy in IgG4-related systemic disease. Am J Surg Pathol 2006; 30:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/74\">",
"      Saeki T, Nishi S, Imai N, et al. Clinicopathological characteristics of patients with IgG4-related tubulointerstitial nephritis. Kidney Int 2010; 78:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/75\">",
"      Cheuk W, Lee KC, Chong LY, et al. IgG4-related Sclerosing disease: a potential new etiology of cutaneous pseudolymphoma. Am J Surg Pathol 2009; 33:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/76\">",
"      Miyagawa-Hayashino A, Matsumura Y, Kawakami F, et al. High ratio of IgG4-positive plasma cell infiltration in cutaneous plasmacytosis--is this a cutaneous manifestation of IgG4-related disease? Hum Pathol 2009; 40:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/77\">",
"      Umemura T, Zen Y, Hamano H, et al. IgG4 associated autoimmune hepatitis: a differential diagnosis for classical autoimmune hepatitis. Gut 2007; 56:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/78\">",
"      Zen Y, Fujii T, Sato Y, et al. Pathological classification of hepatic inflammatory pseudotumor with respect to IgG4-related disease. Mod Pathol 2007; 20:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/79\">",
"      Uehara T, Hamano H, Kawa S, et al. Chronic gastritis in the setting of autoimmune pancreatitis. Am J Surg Pathol 2010; 34:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/80\">",
"      Cheuk W, Chan AC, Lam WL, et al. IgG4-related sclerosing mastitis: description of a new member of the IgG4-related sclerosing diseases. Am J Surg Pathol 2009; 33:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/81\">",
"      Zen Y, Kasahara Y, Horita K, et al. Inflammatory pseudotumor of the breast in a patient with a high serum IgG4 level: histologic similarity to sclerosing pancreatitis. Am J Surg Pathol 2005; 29:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/82\">",
"      Shimatsu A, Oki Y, Fujisawa I, Sano T. Pituitary and stalk lesions (infundibulo-hypophysitis) associated with immunoglobulin G4-related systemic disease: an emerging clinical entity. Endocr J 2009; 56:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/83\">",
"      Haraguchi A, Era A, Yasui J, et al. Putative IgG4-related pituitary disease with hypopituitarism and/or diabetes insipidus accompanied with elevated serum levels of IgG4. Endocr J 2010; 57:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/84\">",
"      Chan SK, Cheuk W, Chan KT, Chan JK. IgG4-related sclerosing pachymeningitis: a previously unrecognized form of central nervous system involvement in IgG4-related sclerosing disease. Am J Surg Pathol 2009; 33:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/85\">",
"      Uehara T, Hamano H, Kawakami M, et al. Autoimmune pancreatitis-associated prostatitis: distinct clinicopathological entity. Pathol Int 2008; 58:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/86\">",
"      Sugimoto T, Morita Y, Isshiki K, et al. Constrictive pericarditis as an emerging manifestation of hyper-IgG4 disease. Int J Cardiol 2008; 130:e100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/87\">",
"      Takikita-Suzuki M, Ishida M, Okabe H. Re-evaluation of IgG4 in systemic fibroinflammatory disease with intracardiac involvement. Hum Pathol 2010; 41:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/88\">",
"      Kamisawa T, Okamoto A, Funata N. Clinicopathological features of autoimmune pancreatitis in relation to elevation of serum IgG4. Pancreas 2005; 31:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/89\">",
"      Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol 2012; 25:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/90\">",
"      Khosroshahi A, Stone JH. Treatment approaches to IgG4-related systemic disease. Curr Opin Rheumatol 2011; 23:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/91\">",
"      Carruthers MN, Stone JH, Deshpande V, Khosroshahi A. Development of an IgG4-RD Responder Index. Int J Rheumatol 2012; 2012:259408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/92\">",
"      Khosroshahi A, Bloch DB, Deshpande V, Stone JH. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 2010; 62:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/93\">",
"      Khosroshahi A, Carruthers MN, Deshpande V, et al. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore) 2012; 91:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/94\">",
"      Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008; 134:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/95\">",
"      Stone JH, Khosroshahi A, Hilgenberg A, et al. IgG4-related systemic disease and lymphoplasmacytic aortitis. Arthritis Rheum 2009; 60:3139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/96\">",
"      Cheuk W, Yuen HK, Chan AC, et al. Ocular adnexal lymphoma associated with IgG4+ chronic sclerosing dacryoadenitis: a previously undescribed complication of IgG4-related sclerosing disease. Am J Surg Pathol 2008; 32:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/55/13178/abstract/97\">",
"      Cheuk W, Tam FK, Chan AN, et al. Idiopathic cervical fibrosis--a new member of IgG4-related sclerosing diseases: report of 4 cases, 1 complicated by composite lymphoma. Am J Surg Pathol 2010; 34:1678.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16155 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-85B74C0F79-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_55_13178=[""].join("\n");
var outline_f12_55_13178=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H43795036\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16601895\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4739538\">",
"      DEFINITION AND HISTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11899448\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H365938\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16601923\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H250672027\">",
"      IgG4-RD associated disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H250672034\">",
"      - Lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16601930\">",
"      Autoimmune pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16601937\">",
"      IgG4-related sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16601951\">",
"      Salivary and lacrimal gland involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179281615\">",
"      Retroperitoneal fibrosis and related disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179281773\">",
"      Aortitis and periaortitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H360095760\">",
"      Thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H360096128\">",
"      Lung and pleural disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16601972\">",
"      Tubulointerstitial nephritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H360095919\">",
"      Other involved organs and tissues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34249877\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H447315085\">",
"      Indications for diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H447315093\">",
"      Diagnostic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1086624\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11899728\">",
"      Postdiagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34249908\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43795020\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43795028\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H447315657\">",
"      Risk of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43795036\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/16155\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/16155|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/25/13721\" title=\"picture 1\">",
"      Autoimmune pancreatitis patient with IgG4 immunostaining",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/42/672\" title=\"picture 2\">",
"      IgG4-related sialadenitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/20/30025\" title=\"picture 3\">",
"      IgG4 immunoperoxidase stain of chronic sclerosing sialadenitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/26/40361\" title=\"picture 4\">",
"      H and E stain of chronic sclerosing sialadenitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40168?source=related_link\">",
"      Autoimmune pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6970?source=related_link\">",
"      Castleman's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=related_link\">",
"      Classification and diagnosis of Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22712?source=related_link\">",
"      Clinical features and diagnosis of thoracic aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22521?source=related_link\">",
"      Clinical manifestations and diagnosis of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34136?source=related_link\">",
"      Clinical manifestations and diagnosis of retroperitoneal fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=related_link\">",
"      Diagnostic evaluation of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=related_link\">",
"      Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11450?source=related_link\">",
"      Epidemiology, risk factors, pathogenesis and natural history of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39080?source=related_link\">",
"      Evaluation of peripheral lymphadenopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15526?source=related_link\">",
"      Fibrosing mediastinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13258?source=related_link\">",
"      IgG subclass deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35078?source=related_link\">",
"      IgG subclasses: Physical properties, genetics, and biologic functions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/15/43257?source=related_link\">",
"      Infiltrative thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/32/16906?source=related_link\">",
"      Interstitial lung disease associated with Sj&ouml;gren's syndrome: Clinical manifestations, evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9927?source=related_link\">",
"      Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14440?source=related_link\">",
"      Sclerosing mesenteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/35/14904?source=related_link\">",
"      Treatment of retroperitoneal fibrosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_55_13179="Spec rep in PHP";
var content_f12_55_13179=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F71105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=13\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F71105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=13\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Participants in PHP programs by specialty, Florida 2007",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Medical practice",
"      </td>",
"      <td class=\"subtitle1\">",
"       Percent of participants",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Orthopedics",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ob/Gyn",
"      </td>",
"      <td>",
"       6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neurology",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Anesthesiology",
"      </td>",
"      <td>",
"       21",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Radiology",
"      </td>",
"      <td>",
"       6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Family Medicine",
"      </td>",
"      <td>",
"       6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       ER",
"      </td>",
"      <td>",
"       18",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Surgery",
"      </td>",
"      <td>",
"       6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pathology",
"      </td>",
"      <td>",
"       6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Psychiatry",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_55_13179=[""].join("\n");
var outline_f12_55_13179=null;
var title_f12_55_13180="Hypovolemia in diarrhea";
var content_f12_55_13180=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Assessment of severity of volume depletion among adults with diarrhea",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Examination",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mild hypovolemia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Moderate hypovolemia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Severe hypovolemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Look at:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mental status",
"       </td>",
"       <td>",
"        Alert",
"       </td>",
"       <td>",
"        Restless, irritable",
"       </td>",
"       <td>",
"        Lethargic or unconscious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Eyes",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Sunken",
"       </td>",
"       <td>",
"        Very sunken and dry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tears",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mouth/tongue",
"       </td>",
"       <td>",
"        Moist, slightly dry",
"       </td>",
"       <td>",
"        Dry",
"       </td>",
"       <td>",
"        Very dry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thirst",
"       </td>",
"       <td>",
"        Increased thirst",
"       </td>",
"       <td>",
"        Thirsty, drinks eagerly",
"       </td>",
"       <td>",
"        Drinks poorly or not able to drink",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Feel:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Skin pinch",
"       </td>",
"       <td>",
"        Goes back rapidly",
"       </td>",
"       <td>",
"        Goes back slowly",
"       </td>",
"       <td>",
"        Goes back very slowly (tenting)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pulse",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Rapid, weak",
"       </td>",
"       <td>",
"        Very fast, weak or nonpalpable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Extent of volume loss",
"       </td>",
"       <td>",
"        &lt;5 percent of body weight",
"       </td>",
"       <td>",
"        from 5 to 10 percent of body weight",
"       </td>",
"       <td>",
"        &gt;10 percent of body weight",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Swerdlow DL, Ries&nbsp;AA. JAMA 1992; 267:1495.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_55_13180=[""].join("\n");
var outline_f12_55_13180=null;
var title_f12_55_13181="Guidance for PrEP against HIV";
var content_f12_55_13181=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation and monitoring of patients prior to initiation and during administration of pre-exposure prophylaxis against HIV",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Before initiating PrEP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Determine eligibility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Document negative HIV antibody test(s) immediately before starting PrEP medication.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Test for acute HIV infection if patient has symptoms consistent with acute HIV infection.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Confirm that patient is at substantial, ongoing, high risk for acquiring HIV infection.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Confirm that calculated creatinine clearance is &ge;60 mL per minute (via Cockcroft-Gault formula).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Other recommended actions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screen for hepatitis B infection; vaccinate against hepatitis B if susceptible, or treat if active infection exists, regardless of decision about prescribing PrEP.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Screen and treat as needed for STIs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Perform pregnancy testing&nbsp;for women.&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Beginning PrEP medication regimen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span class=\"indent1\">",
"         Prescribe 1 tablet of Truvada (TDF [300 mg] plus FTC [200 mg]) daily.",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span class=\"indent1\">",
"         In general, prescribe no more than a 90-day supply, renewable only after HIV testing confirms that patient remains HIV-uninfected.",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span class=\"indent1\">",
"         If active hepatitis B infection is diagnosed, consider using TDF/FTC for both treatment of active hepatitis B infection and HIV prevention.",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span class=\"indent1\">",
"         Provide risk-reduction and PrEP medication adherence counseling and condoms.",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Follow-up while PrEP medication is being taken",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Every&nbsp;two to three&nbsp;months, perform an HIV antibody test; document negative result.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evaluate and support PrEP medication adherence at each follow-up visit, more often if inconsistent adherence is identified.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Every&nbsp;two to three&nbsp;months, assess risk behaviors and provide risk-reduction counseling and condoms. Assess STI symptoms and, if present, test and treat for STI as needed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Every&nbsp;six months, test for STI even if patient is asymptomatic, and treat as needed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Every three months, check blood urea nitrogen and serum creatinine. Discontinue PrEP if creatinine clearance decreases by 20 percent or to &lt;50 mL per minute.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Every&nbsp;three months, assess pregnancy status for women on&nbsp;PreP&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        On discontinuing PrEP (at patient request, for safety concerns, or if HIV infection is acquired)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perform HIV test(s) to confirm whether HIV infection has occurred.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If HIV-positive, order and document results of resistance testing and establish linkage to HIV care.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If HIV-negative, establish linkage to risk-reduction support services as indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If active hepatitis B is diagnosed at initiation of PrEP, consider appropriate medication for continued treatment of hepatitis B.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     HIV: human immunodeficiency virus; PrEP: Pre-exposure prophylaxis; STI: sexually transmitted infection; TDF: tenofovir disoproxil fumarate; FTC: emtricitabine.&nbsp;",
"    </p>",
"    <div class=\"footnotes\">",
"     <br/>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted&nbsp;from:",
"     <br>",
"      <ol>",
"       <li>",
"        CDC. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR 2011;60:65&ndash;8.",
"       </li>",
"       <li>",
"        CDC. Interim Guidance for Clinicians Considering the Use of Preexposure Prophylaxis for the Prevention of HIV Infection in Heterosexually Active Adults. MMWR 2012; 61:586-589",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_55_13181=[""].join("\n");
var outline_f12_55_13181=null;
var title_f12_55_13182="Drugs causing thrombopenia";
var content_f12_55_13182=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F62516&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F62516&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs with evidence for a causal relation to thrombocytopenia*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td>",
"          Abciximab (ReoPro)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Acetaminophen (Tylenol, Panadol, and others)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Acetazolamide (Diamox and Sequels)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Adefovir (Hepsera)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Alprenolol (Aptin)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Aminoglutethimide (Cytadren)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Aminosalicylic acid (Paser)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Amiodarone (Cordarone and Pacerone)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Amphotericin B (Amphocin and Fungizone)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ampicillin (Omnipen, Apo-Ampi, and others)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Atorvastatin (Lipitor)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Captopril (Capoten)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Carbamazepine (Tegretol, Carbatrol, and others)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Chlorothiazide (Diuril)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Chlorpromazine (Thorazine)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Chlorpropamide (Diabinese)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cimetidine (Tagamet)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Clidinium/chlordiazepoxide (Librax)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Clopidogrel (Plavix)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Danazol (Danocrine)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Deferoxamine (Desferal)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Diatrizoate meglumine/diatrizoate sodium (Gastrografin, MD-76, and others)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Diazepam (Valium)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Diazoxide (Proglycem)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Diclofenac (Cataflam, Voltaren, and others)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Diethylstilbestrol (Stilphostrol)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Digoxin (Lanoxin)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Eflornithine (Vaniqa)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Eptifibatide (Integrilin)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ethambutol (Myambutol)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Etretinate (Tegison)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Famotidine (Pepcid)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Fluconazole (Diflucan)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Glyburide (Dia&beta;eta, Micronase, and others)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Gold (Ridaura, Solganal, and others)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Haloperidol (Haldol)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hydrochlorothiazide (Microzide)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ibuprofen (Advil, Motrin, and others)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Inamrinone (Inocor)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Indinavir (Crixivan)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Interferon alfa (Roferon-A and Intron A)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Iopanoic acid (Telepaque)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Isoniazid (Isotamine and Nydrazid)",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td>",
"          Levamisole (Ergamisol)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Linezolid (Zyvox)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Lithium (Lithionate, Eskalith, and others)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Lopinavir/ritonavir (Kaletra)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Meclofenamate (Meclomen)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Mesalamine (Apriso, Asacol, and others)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Methicillin (Staphcillin)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Methyldopa (Aldomet, Apo-Methyldopa, and others)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Minoxidil (Rogaine)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Nalidixic acid (NegGram and others)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Naphazoline (Clear Eyes, Privine, and others)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Naproxen (Aleve, Midol, and others)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Nitroglycerin (Nitrogard, Nitroglyn, and others)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Oxaliplatin (Eloxatin)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Oxprenolol (Trasicor)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Oxyphenbutazone (Tanderil and others)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pentoxifylline (Pentoxil, Trental, and others)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Phenytoin (Dilantin and Phenytek)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Piperacillin (Pipracil, Zosyn)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Procainamide (Procan SR, Apo-Procainamide, and others)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Quinidine (Quinaglute, Cardioquin, and others)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Quinine (Quinamm, Quindan, and others)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ranitidine (Zantac and others)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Rifampin (Rifadin)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Rituximab (Rituxan)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Simvastatin (Zocor)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sulfamethoxypyridazine (Sulfamthoxazole)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sulfapyridine (Dagenan)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sulfasalazine (Azulfidine, EN-tabs, and others)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sulfathiazole",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sulfisoxazole (Gantrisin)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sulindac (Clinoril)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Tamoxifen (Nolvadex)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Teicoplanin (Targocid and Targosid)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Terbinafine (Lamisil)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Thiothixene (Navane)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ticlopidine (Ticlid)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Tirofiban (Aggrastat)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Tolmetin (Tolectin 600 and Tolectin DS)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Trastuzumab (Herceptin)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Trimethoprim/sulfamethoxazole (Bactrim, Sulfatrim, and others)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Valproic acid (Depacon, Depakene, and others)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Vancomycin (Vancocin)",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The criteria for determining the level of evidence as \"definite\" or \"probable\" are described in \"Drug-induced thrombocytopenia.\" For this table, we considered that two reports with \"probable\" evidence provided validity for a causal relation of the drug to thrombocytopenia, similar to one report with \"definite\" evidence. The complete list of all drugs that have been described in published case reports, together with the levels of evidence, is available at www.ouhsc.edu/platelets.",
"    <div class=\"footnotes\">",
"     *US trade names shown in parentheses.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James N. George, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_55_13182=[""].join("\n");
var outline_f12_55_13182=null;
var title_f12_55_13183="Evaluation of febrile HIV child";
var content_f12_55_13183=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagnostic evaluation of acutely febrile HIV-infected children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 344px; height: 481px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_55_13183=[""].join("\n");
var outline_f12_55_13183=null;
